Genetic Landscape of Common Epilepsies: Advancing towards Precision in Treatment

Abstract

Epilepsy, a neurological disease characterized by recurrent seizures, is highly heterogeneous in nature. Based on the prevalence, epilepsy is classified into two types: common and rare epilepsies. Common epilepsies affecting nearly 95% people with epilepsy, comprise generalized epilepsy which encompass idiopathic generalized epilepsy like childhood absence epilepsy, juvenile myoclonic epilepsy, juvenile absence epilepsy and epilepsy with generalized tonic-clonic seizure on awakening and focal epilepsy like temporal lobe epilepsy and cryptogenic focal epilepsy. In 70% of the epilepsy cases, genetic factors are responsible either as single genetic variant in rare epilepsies or multiple genetic variants acting along with different environmental factors as in common epilepsies. Genetic testing and precision treatment have been developed for a few rare epilepsies and is lacking for common epilepsies due to their complex nature of inheritance. Precision medicine for common epilepsies require a panoramic approach that incorporates polygenic background and other non-genetic factors like microbiome, diet, age at disease onset, optimal time for treatment and other lifestyle factors which influence seizure threshold. This review aims to comprehensively present a state-of-art review of all the genes and their genetic variants that are associated with all common epilepsy subtypes. It also encompasses the basis of these genes in the epileptogenesis. Here, we discussed the current status of the common epilepsy genetics and address the clinical application so far on evidence-based markers in prognosis, diagnosis, and treatment management. In addition, we assessed the diagnostic predictability of a few genetic markers used for disease risk prediction in individuals. A combination of deeper endo-phenotyping including pharmaco-response data, electro-clinical imaging, and other clinical measurements along with genetics may be used to diagnose common epilepsies and this marks a step ahead in precision medicine in common epilepsies management.

1. Introduction

Epilepsy, one of the common neurological disease, is characterized by recurrent unprovoked seizures, affecting people of all age, gender, race and geographical location. Nearly 50 million people are affected worldwide with a prevalence rate of 5–10 per 1000 people [1] which accounts for more than 0.5% of the global burden of the disease [2]. Due to the vast heterogeneity associated with the genetics of common epilepsies, it is diagnosed by clinical phenotyping. There are other risk factors like age at onset, and comorbidities (such as psychiatric disorder, intellectual disability and others) that contribute to epilepsy etiology. With time, the disease classification has been dynamic, in coherent with the updated research findings. Based on seizures, epilepsy classification has evolved into different types which are: focal epilepsy, generalized epilepsy, combined focal and generalized epilepsy, and unknown epilepsy. Additionally, according to etiology it is classified as structural, genetic, infectious, metabolic, immune and unknown [3].

Some of these epilepsy types are highly prevalent in the population than others, and are therefore known as common epilepsies. Such epilepsies are multifactorial and exhibit complex pattern of inheritance, unlike rare epilepsies that display Mendelian inheritance. Of the total patients with active epilepsy (patients who are diagnosed with epilepsy or seizure disorder and either are currently taking medication to control it, or having one or more seizures in the past year, or both), approximately 95% are affected with common epilepsies whereas, 5% suffer from the rare form. The common and rare epilepsies are represented as in Figure 1 as per the latest International League Against Epilepsy (ILAE) etiologic classification of epilepsy, albeit it should be noted that there is no formal classification of rare epilepsy syndromes by ILAE. Common epilepsies broadly comprise generalized and focal epilepsies. Generalized epilepsy encompass genetic generalized epilepsies (GGEs), with its sub-types like juvenile myoclonic epilepsy (JME), childhood absence epilepsy (CAE), juvenile absence epilepsy (JAE), and epilepsy with generalized tonic-clonic seizure (EGTCS) on awakening. Similarly, localization based focal epilepsies include temporal lobe epilepsy (TLE) and cryptogenic focal epilepsy (CFE) [4]. However, of the total GGEs, 1–2% include rare monogenic epilepsies such as autosomal dominant nocturnal frontal lobe epilepsy, benign familial neonatal seizures, early onset epilepsy, myoclonic astatic epilepsy, epilepsy with myoclonic absences, eyelid myoclonic with absences and absence status epilepsy [5,6]. Findings from traditional twin studies and familial aggregation studies revealed that genetic factors can contribute to both focal as well as generalized epilepsies [7]. Clinical studies also suggested that one or more genetic factors are involved in approximately 70–80% of the epilepsy cases, whereas the remaining 20–30% of cases clearly hold an acquired factor such as tumor, stroke, or head injury [8]. Several efforts have been made to identify the genetic variants that are associated with etiology of epilepsy or have an impact in the disease development. Advancement in genomic technologies like sequence-based approaches including massive parallel sequencing, whole-genome sequencing, whole-exome sequencing and targeted gene panel have catalogued numerous potential genetic variations associated with epilepsy. In addition, technologies like comparative genomic hybridization and single nucleotide polymorphism (SNP) genotyping arrays also allowed genome-wide screening of variants in large cohorts in a cost-effective and time-saving manner. These genetic variants cover a large spectrum of variation, from SNPs to the loss or gain of base pairs along with de-novo variants (genetic variants that are first time detected in proband and are absent in parents’ genome) that are detected in some cases. Copy number variations (CNVs) and rare variants of higher effect size have been identified for GGE, CAE and other common epilepsy phenotypes [9]. Genetic variants associated with epilepsy have been found in hundreds of different genes, which may predict disease related phenotypes. The intermediate domain between genotype and phenotype is occupied by an endo-phenotype (heritable trait which may be biochemical, endocrine, electro-physiological, cognitive, or anatomical in nature) [10]. Hence along with genetics, investigating the basis of endo-phenotype could facilitate the layered understanding of subtle features of specific genes in disease physiology. Mounting evidences indicated that quantitative magnetic resonance imaging (QMRI) can detect aberrant fronto-thalamic structure such as loss in thalamic volume and increased mesio-frontal and fronto-basal grey matter concentration in patients with JME, and the white matter microstructural alterations in mesial temporal lobe epilepsy (MTLE) can serve as potential endo-phenotype [9]. Thus, an integrative understanding of endo-phenotype along with genetic risk factors may improve the disease risk predictability. This is ultimately the resolution of precision therapy and the intention of exploring the disease genetics.

Traditional genetic studies like candidate gene study, linkage study, genome-wide association studies (GWAS) are based on screening of the whole genome for the genotype—phenotype association to get insight about genetic architecture and disease susceptibility of complex disease. Several GWAS have been performed to explore the disease genetics in epilepsy. Initially, the findings of GWAS were largely negative due to the small sample size and high genetic heterogeneity in epilepsy [11,12]. Later, several international consortiums joined hands for integrative efforts to explore the disease genetics and its implications. These collaborative efforts of different groups working in the international epilepsy research community made two major advancements in the field. First, large sample size in studies assured a sufficient statistical power for successful genetic association. One of the prominent consortiums established to address the inconsistencies in genetic data is the ILAE. This group published the largest GWAS to date that included 15,212 epilepsy cases and 29,677 controls resulting in the identification of 16 statistically significant risk alleles [13]. Secondly, the consortiums provided a broader phenotypic spectrum by utilizing multi-disciplinary approaches to understand the disease heterogeneity. With this iterative process of cooperative effort, ILAE came up with the newer classifications of epilepsy based on seizure type, disease etiology and clinical factors [14] after almost three decades since the last ILAE classification in 1989 [15]. Several other consortiums have laid the foundation in this field, for example Epi4K majorly explores the genetics of common forms of epilepsy and epileptic encephalopathies, including the prognostic determinants of these disease. Another consortium, Epi25K is the unification of Epi4K, EPIGEN, EuroEPINOMICS, the Epilepsy Phenome/Genome Project, EpiPGX, SANAD, and EpiCURE consortiums which aims to combine the genotype, phenotype, and genomic sequencing data and to perform joint analyses of the data to expedite genetic biomarker discovery in all epilepsies.

Enormous genetic data is already available on common epilepsies as well as on rare epilepsies across diverse populations which made strides in understanding the genetic architecture of epilepsies. Still much work is needed for identifying the genotype-phenotype correlation for common epilepsies due to the complex nature of the genetics involved. Elucidating the genetic basis of common epilepsy subtypes like rare monogenic epilepsies along with the genome-environment interaction involved in their multifactorial etiology may provide important insights into the pathophysiological mechanism, thus may accelerate the process of accomplishing precision medicine. In this review, we performed a comprehensive state-of-art literature review concerning the genetics of different subtypes of common epilepsies i.e. GGE (CAE, JME, JAE, EGTCS), TLE and CFE. A literature search was performed in PubMed. Further, we used online available databases like ClinVar, Online Mendelian Inheritance in Man (OMIM), Epilepsy Genetic Association Database (epiGAD), Phenotype-Genotype Integrator (PheGenI), DisGeNET and GWAS Catalog to retrieve all genetic markers. Here, we consolidated genetic variants associated with different subgroups of common epilepsies from published evidences. Through this review, we made an attempt to delineate the different subgroups of common epilepsies based on the comprehensive knowledge from genetic association studies. Along with the genes / genetic variants, the substantial role of deep phenotyping may aid in the characterization of the biological functions driving the pathophysiological changes in epilepsy. Identification of such associated genetic variants might presage the end of the diagnostic odyssey and will fuel the field of precision medicine. The discovery of such genetic variants will give direction to unfold the complex genetics of common epilepsies and will encourage researchers to elucidate new diagnostic, prognostic biomarker and new therapeutic targets for epilepsy treatment. This knowledge can be used for clinical practice and genetic counselling. In this paper we have also assessed such genetic markers based on their diagnostic predictability (i.e. sensitivity and specificity) which are commercialized and potentially effective in accurate genetic testing for disease diagnosis by various companies. This will be a leap in epilepsy translation from bench to bedside application.

2. Genetic Studies of Common Epilepsies

Epilepsy genetics began its journey from the identification of associated genes and/or their causal variants in Mendelian epilepsies, where a single mutation in a gene can predict the occurrence of disease. However, such strong associations are not detected for the complex forms of epilepsy due to the involvement of multiple factors, including genetic and non-genetic factors. Along with advanced genetic technologies like GWASs and sequencing-based analysis, newer analytical methodologies like polygenic risk score (PRS) can be used. This will help to calculate the genetic load conferred by a set of risk variants to identify the carrier individuals at higher risk. This score can be derived from SNP chips or whole genome sequencing (WGS) for predicting disease risk and estimating heritability. Initial genetic research was driven towards implications of ion channel genes in genetic epilepsies. This led to the emergence of the channelopathy era for genetic epilepsies [16].

Apart from ion channel genes, which account for a significant proportion of genetic epilepsies, other genes have been identified to be associated with epilepsies with a genetic origin. These genes manifest the diverse mechanisms involved in the pathophysiology and introduced new avenues for therapeutics. Pathways leading to alterations in ion channel structure and their synthesis, in the release and reuptake of neurotransmitters and defects in transporter and post-synaptic receptor activation may result in the loss of function of γ-aminobutyric acid (GABA)-ergic and gain of function of glutamatergic neurotransmission. Such changes may cause an imbalance in the functioning of the excitatory and inhibitory neurons, and eventually disturb the neuronal homeostasis, leading to neuronal hyper-excitability. This is a common patho-genetic mechanism known for all genetic epilepsies [17,18,19] (Figure 2). Genome-wide approaches may assist in the discovery of previously unsuspected markers associated with disease susceptibility, as most genetic variants belong to non-coding regions and cannot justify their biological relevance in disease etiology. This may be due to the small sample size and large heterogeneity associated with epilepsy [11,12]. Genetic findings of all common generalized and focal epilepsies are discussed in detail below to underpin the genetic mechanism of these epilepsies.

2.1. Genetic Generalized Epilepsy (GGE)

The most common epilepsy type, GGE, formerly known as idiopathic generalized epilepsy (IGE) covers one fourth of all epilepsies. Absence seizures, myoclonus seizures and generalized tonic-clonic seizures (GTCS) are commonly observed in various combination in GGE patients. Based on seizure types and age at disease onset, GGE is divided into common and rare sub-syndromes [20]. The most common subtypes of GGE are CAE, JME, JAE, and EGTCS [5]. Likewise, the rare sub-syndromes of GGE includes autosomal dominant nocturnal frontal lobe epilepsy, benign familial neonatal seizures and others. Twin studies have shown that epilepsy recurrence rate is higher in monozygotic twin in comparison to dizygotic twins, which provide a strong support for the role of genetics in GGE [6]. In monozygotic twins, the recurrence risk of the common GGE syndromes is 70–95% and that for first degree relatives is 5–8% [21]. Since the risk to have GGE in siblings is lower than the expected rate of a recessive inherited trait (25%) and dominantly inherited trait (50%) [20], this suggests that multiple genes/genetic variants together result in GGE phenotype thereby indicating its polygenic inheritance. Therefore, all susceptible genes can collectively determine the disease risk to GGE [6]. Like other complex diseases, common genetic variants associated with GGE show low impact and rare variants show high impact in epilepsy risk [20]. Based on the GGE subtype, the role of these associated genes in the pathophysiology are discussed in details in the following sections and are summarized in Table 1.

2.1.1. Childhood Absence Epilepsy (CAE)

One of the GGE subtypes, CAE, is idiopathic and characterized by multiple typical absence seizure accompanied by asynchronous, bilateral, 2.5–4 Hz generalized spike and wave epileptiform discharges on the electroencephalogram (EEG). The slow epileptiform episodes are brief discharges (4–20 s) with a frequency of 10–100/day with abrupt onset and termination. This type of epilepsy typically begins between 3-8 years of age with a peak incidence at 5–7 years of age [22] and a prevalence rate of 1–4/50 people with epilepsy (2–8% of total people with epilepsy) [23]. Most of the genes associated with CAE are ion channel genes, like calcium channel, GABA receptor, acetylcholine receptor and so on. The calcium channel genes CACNA1H and CACNG3 are highly associated with CAE [24] particularly in Han Chinese population [25]. Some of the most important genes related known with functional role in CAE are discussed in detail in the following sections. Genetic investigations in patients with CAE have demonstrated the role of GABA A and B receptor genes such as GABRG2, GABRA1, GABRB3, GABAB1, GABAB2 genes which have been implicated in epileptogenesis in such patients. Furthermore, linkage and mutational analysis suggested the involvement of chloride channels genes, CLCN2, as a susceptibility locus in a subset of CAE [26].

Voltage-Gated Ion Channels

The flow of ions across the neuronal membrane determines the extent of neuronal excitability. Any disturbance in the ion channel structure and function leads to nerve cell hyper-excitability causing epilepsy. Ion channel genes contribute approximately 25% of all the genes identified till date in epilepsy [27]. Based on the nature of ion transport, these genes are divided into voltage-gated (e.g., CACNA1H, CACNG3, CLCN2), and ligand-gated (e.g. CHRNA4, GABRA1, GABRB3, GABRG2, GRM4).

Calcium Channel Genes

Among the voltage-gated ion-channels, CAE is predominantly associated with calcium channels. These channels regulate the release of the excitatory neurotransmitter, glutamate by the pre-synaptic neuron modulating electrogenic properties of dendrites, leading to hyper-excitability [28]. Depending on the voltage required for their activation, calcium channels are divided into low-voltage activated (T-type) channel that belong to CaV₃ family and high-voltage activated (L-type, P/Q-type, N-type, R-type) channel belonging to CaV₁, and CaV₂ family. T-type calcium channels involves CACNA1G (CaV_3.1), CACNA1H (CaV_3.2) and CACNA1I (CaV_3.3) genes encoding the alpha subunit of these channels [29]. A mutational analysis in Han Chinese population of CAE patients identified the presence of 12 missense mutations in CACNA1H gene [30]. Another study identified the variant rs2745150 located on intron 11 of CACNA1H gene to be significantly associated with CAE [31]. The common variant, rs9934839 in exon 9 and a common haplotype block in CACNA1H gene were also significantly associated with CAE in a case-control study in Chinese patients [25]. In vitro studies suggested that mutations in the CACNA1H gene cause the generation of the slow wave discharges in EEG pattern in absence seizures via increasing its T-type calcium channel activity [32]. In human studies, voltage-gated calcium channel auxiliary subunit gamma 3 (CACNG3) gene is found to be associated with CAE, encodes type I transmembrane AMPA (α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid) receptor regulatory protein (TARP). TARP protein regulates both trafficking and channel gating of the AMPA receptors. These AMPA receptor are activated by glutamate binding and have an important role in ictogenesis and epileptogenesis [33,34,35]. These are predominantly present at excitatory synapse. Everett et al. found the significant association of CACNG3 polymorphism like rs4787924, rs965830, rs2214437 and a haplotype with CAE [26]. All these variants are present in intronic region. These variants might affect the splicing site which may affect TARP protein composition and synthesis ultimately resulting in disturbance in trafficking and gating of AMPA receptor. It may increase AMPA-mediated postsynaptic conductance causing hyper-excitability which generate seizures. Based on these evidences, association of the calcium channel encoding gene variants with human absence epilepsy, specifically CAE was proposed.

Ligand-Gated Channels

GABA A Receptor Genes: Another type of ion-channel genes that were observed to be associated with CAE pathophysiology are the ligand-gated GABA receptors (GABARs). The gamma-aminobutyric acid type A receptor subunit alpha1 (GABRA1) gene encodes alpha-1 (α1) subunit, of the GABA_AR protein. GABA_AR is pentameric having five subunits that arise from seven subunit families: alpha, beta, gamma, delta, rho, theta and epsilon [36]. This receptor acts as a channel for chloride ions to cross the cell membrane. These chloride ions helps in hyper-polarization of post-synaptic membrane potential and inhibits action potential generation [37]. These are chloride channels which act as neurotransmission inhibitor at the synapse [38]. A missense variation R43Q (rs121909673) in GABRG2 gene was the first GABA type A receptor (GABA_AR) found to be associated with CAE. In vitro studies suggest that the genetic variant may abolish the benzodiazepine (drug which increases GABA activity) sensitivity [39] through imprecise assembly of GABRG2 subunit with the receptor complex that expedite deactivation of GABAR [38] and also reduces the expression of cell surface GABARs [40,41,42,43]. This termination of the benzodiazepine-induced potentiation of GABARs and deficit of cell surface expression of GABARs may lead to the reduction in synaptic inhibition and neuronal hyper-excitability enhancing risk for CAE [39]. Another study revealed an association between GABA_AR subunit β3 (GABRB3) and CAE [44]. Urak et al. defined 4-haplotypes using 13 SNPs between the exon 1a promoter and the beginning of intron 3 within the GABRB3 gene region, of which one haplotype was found to be significantly associated with CAE. In vitro studies found that this haplotype reduced the expression of GABRB3, and could be a potential factor in the development of CAE [45]. Another study suggested that SNPs P11S (rs25409), S15F (rs121913126), and G32R (rs71651682) in the same gene result in hyperglycosylation of the GABRB3 protein causing impairment in maturation and trafficking of GABAR from endoplasmic reticulum to cell surface resulting in reduced GABA-evoked currents leading to generation of absence seizures [46,47].

Glutamate receptor: The glutamate metabotropic receptor 4 (GRM4) encode the group III mGluR4 (metabotropic glutamate receptor type 4) and regulate the release of glutamate and GABA in the thalamo-cortical network. Studies on animal models have shown that perturbation in mGlu4 receptor function has a role in increasing susceptibility for absence seizure through modulation of glutamate and GABA release [48,49,50]. Genetic variants like rs9380405, rs4711374 are found significantly associated with CAE [51]. These intronic variants might affect the GRM4 expression which lead to imbalance in glutamate and GABA release and thus increase susceptibility for the epilepsy.

Acetylcholine Receptor Genes: A silent polymorphism 594C/T (rs121909580) in the cholinergic receptor nicotinic alpha 4 subunit (CHRNA4) gene is found with a higher frequency of T allele in epilepsy cases than control subjects [36]. Hence it can be a susceptible allele for epilepsy which might determine seizure threshold and cause neuronal excitability [52].

µ-Opioid Receptor Gene: Involvement of µ-opioid receptor gene (OPRM1) which encode opioid receptor, has been postulated in the pathogenesis of absence epilepsy. The receptor belongs to the family of seven-transmembrane G protein-coupled potassium channel receptors. This receptor is target for endogenous peptide like β-endorphin which act as neuromodulator [53]. An experiment in WAG/Rij rats which are regarded as a genetic model of absence epilepsy showed that administration of µ- receptor agonist D-Ala-N-methyl-Phe4-Gly-olenkephalin (DAMGO) resulted in dose related increase in slow wave discharge while pretreatment with µ- receptor antagonist, β -funaltrexamine (β –FNA) diminished the action of DAMGO suggesting that activation of µ-opioid receptor increase the epileptic activity. Thus, animal studies provide evidence for their role in absence epilepsy [54,55,56]. A variant Asn40Asp (rs1799971) in opioid receptor has been found significantly associated with CAE phenotype [57]. This variant increases the binding affinity of β-endorphin three time more than the wild type allele. This in turn, activates opioid receptor which alters signal transduction by activation of G protein-coupled potassium channels [56]. This enhances the thalamic neuronal excitability and confers susceptibility to idiopathic absence epilepsy (IAE which constitute both CAE and JAE) [57]. However, replication study on Caucasian population did not find any association of this variant with IAE [58]. It may be due to lack of power for IAE.

Solute Carrier Transporters

Solute carrier family 6member 3 (SLC6A3/DAT1) gene encoding a dopamine transporter, is a member of the sodium- and chloride-dependent neurotransmitter transporter family. In 3′ UTR region of this gene, a 40bp tandem repeat referred to as a variable number tandem repeat (VNTR), is present in 3 to 11 copies. Variation in the number of repeats, as increase in the nine-copy allele, was found associated with 130 patients with IAE compared with 220 ethnically matched control subjects [59]. This study also found association of this polymorphism with a reduced seizure threshold during alcohol withdrawal [60]. An in vivo study found that dopaminergic transporter SLC6A3 mRNA levels are significantly lower in the brains of seizure-naïve genetically epilepsy-prone rats [61], suggesting that the nine-copy allele of the 40 bp repeat polymorphism in DAT gene modulates neuronal network excitability and contributes to the epileptogenesis of IAE.

Unclassified

Leucine rich repeat LGI family member 4 (LGI4) present on chromosome 19q13.1 show an autosomal recessive mode of inheritance. Function of this gene is not known in epilepsy but mutation in this gene might affect neuronal cell migration, axon guidance, or synaptogenesis. A study by Gu. W et al. showed that strong genotypic association exists between CAE and the 1914 GC/AT dinucleotide exchange polymorphism in exon 9 of LGI4. High frequency of homozygous 1914 GC/GC genotype in CAE patients suggests an autosomal recessive variant causes greater susceptibility [62].

2.1.2. Juvenile Myoclonic Epilepsy (JME)

Since the first clinical and imaging description of JME was given by Janz and Christian, is also known as JME of Janz [63]. JME is characterized by myoclonic jerks (quick jerks of the arms or legs), GTCSs, and sometimes, absence seizures. Its onset typically begins around adolescence (between 12 and 18 years of age) in otherwise healthy children [64]. JME affects 5–10% of all cases of epilepsy which constitutes 18% of all cases of GGE [65]. Heritability and linkage analysis have revealed various genes associated with JME. GABRA1 at 5q34-q35, EF-hand domain containing 1 (EFHC1) at 6p12 and SLC2A1 at 1p35–p31 are loci discovered through linkage studies. GABRA1, EFHC1, CLCN2 are putative gene for JME while CACNB4 is not considered putative gene, because it has not been replicated [66]. rs3743123 (CX36), rs2029461 (GRM4), rs3918149 (BRD2) showed significant association with JME in more than one population [67]. Variation in EFHC1 is most commonly observed in families with JME [68,69]. This gene encodes microtubule-associated protein which is involved in cell division and neuronal migration. In vitro studies showed that EFHC1 variants cause disruption of radial glial scaffold which are progenitor cells for cortical development and thus impair radial migration [70,71]. This causes micro-dysgenesis as observed in JME patients [72]. Therefore, these defects during corticogenesis may damage epileptic circuitry during brain development [73].

Potassium Ion Channels

Potassium ion channel is one of the most divergent ion channel family. The KCNQ2 and KCNQ3 (potassium voltage-gated channel subfamily Q member 2 and member 3, respectively) encoding protein subunits KV7.2 and KV7.3 are found expressed throughout different brain regions which can form homo and hetero-tetrameric channels. These channel conduct slowly activating and deactivating current elicited at subthreshold membrane potentials, the so-called M-current. These M-currents are required for the control of membrane potential and prevent neuronal firing. Polymorphisms rs1801545 and rs74582884 in KCNQ2 and KCNQ3 respectively are found to be associated with JME [74]. Other potassium ion channel genes are also found associated with different GGE which are tabulated in Table 1. These variants might affect the channel gating and thus play a role in epilepsy etiology.

Table 1. Overview of the common epilepsyassociated genetic variants.

Sl. No.	Gene/Loci	Gene Family	SNP/Genetic Variant	Risk Allele	Protein Change	GMAF	p-Value	OR (CI)	Country	Reference
GGE
1	SLC4A3	Solute carrier transporter family	2600G/A	A	A867D	-	0.021	1.48 (1.03–2.14)	Germany	[75]
2	CACNA1A	Calcium channel	SNP 8 (SNP in exon 8)	A	-	-	0.00033	1.8 (1.3–2.4)	USA	[76]
3	CHRNA4	Acetylcholine receptor	rs1044396	T	S543S	0.323	0.0126	4.9 (1.71–14.04)	Taiwan	[77]
			rs1044394	T	-	0.136	0.02	3.57 (1.31–9.72)	Germany	[52]
4	D18S474 locus/18q12	-	-	D18S474 8- and 9-	-	-	<0.001	-	Italy	[78]
5	GABRA6	GABA A receptor	rs3219151	T	-	0.43112	<0.001	3.6 (2.1–5.9)	South India	[79]
6	GABARG	GABA A receptor	rs211037	T	-	0.371605	0.004	7.36	Egypt	[80]
7	GRIK	Glutamate receptor	GRIK tetra-nucleotide polymorphism	9 repeat allele	-	-	0.004	1.26 (1.08–1.47)	Germany	[81]
8	GRM4	Glutamate receptor	rs9380405	T	-	0.69	0.003	-	Germany	[51]
			rs937039	G	-	0.257987	0.0038	-
			rs2451334	A	-	0.163339	0.0118	-
			rs2029461-rs2451334-rs745501-rs2499697-rs937039	TGTAA	-	0.402157,0.163339,0.330471, 0.078474, 0.25798	0.0069	3.54 (1.42–8.83)	Jordan	[82]
9	Haptoglobin (Hp)	-	Hp*1	Hp*1	-	-	<0.001 (Hp*1/*1 vs. other types of epilepsy vs. controls in individuals containing *B/*B genotype in ACP1	0.72 (0.011–0.58)	Italy	[83]
10	KCNJ3	Potassium channel gene	T1038C	T	-	-	0.051	1.4 (1.0–1.9)	UK	[84]
11	KCNJ10	Potassium channel gene	rs1130183	C	R271C	0.014776	0.03	0.69 (0.50–0.95)	Germany	[85]
12	KCNMB3	Potassium channel gene	delA750	-	-	-	0.016	1.52 (1.05–2.21)	Germany	[86]
13	KCNQ2	Potassium channel gene	rs1801545	C		0.069286	0.01	1.62 (1.12–2.34)	Germany	[74]
14	KCNQ3	Potassium channel gene	rs74582884	A	P574S	0.0015	0.008	-	India
15	ME2	Enzyme	rs674351- rs584087 - rs585344 - rs608781 - rs642698 - rs674210 - rs645088 - rs649224 - rs654136	A-A-C-A-G-A-C-C-A	-	0.287141, 0.269169, 0.270168, 0.164736, 0.260783, 0.270767, 0.272364, 0.15615	-	6.1 (2.9–12.7)	New York	[87]
16	MTHFR	Methylene tetrahydrofolate reductase	rs1801133/677C>T	T	A222V	0.24	0.01	2.26 (1.13–4.5)	Scotland	[88]
17	COPZ2	Coatomer subunit zeta-2	rs72823592	A	-	0.103834	9.3 × 10–9	0.77 (0.71–0.83)	Austria, Belgium, Denmark, Germany and the Netherlands	[89]
18	SCN1A	Sodium channel gene	rs8191987	G	-	0.225439	0.03	-	UK	[90]
			rs16851381	G	-	0.166134	0.05	-
			rs2298771	G	-	0.2115	0.002	-
19	SCN2A	Sodium channel gene	rs2060199	A	-	0.53	0.04	-
			rs935403	-	-	-	0.03	-
			rs3943809	G	-	0.202	0.04	-
20	SCN8A	Sodium channel gene	rs303777	A	-	0.297724	0.007	-
21	SLC12A5	Transporter	c.3145 C > T	T	R1049C	-	0.044	9.61 (0.8–503.6)	Canada	[91]
22	SYN II	Membrane trafficking	rs37733634	-	-	-	<0.001	2.57 (2.0–3.2)	South India	[79]
			rs3773364	G	-	0.269968	0.02	1.55 (1.06–2.26)	North India	[87]
23	TAP-1A	Transporter	333Val-637Asp	-	333V-637D	-	0.02	0.47	Tunisia	[92]
24	TAP-1C	Transporter	333Ile-637Asp	-	333I-637D	-	0.03	4.3
25	VAMP2	Vesicle-associated membrane protein (VAMP)/synaptobrevin family	26 bp Ins/Del	ins/del*	-	-	0.042	0.474 (0.230–0.978)	Turkey	[93]
26	SYT11	Synaptotagmin XI	33-bp repeats in promoter region	C	-	-	<0.001	2.317 (1.503–3.573)
27	VRK2	Vesicle-associated membrane protein (VAMP)/synaptobrevin family	rs13026414	T	-	0.224641	2.5 × 10–8	-	Finland, USA, Australia, Canada, Belgium, UK, Republic of Ireland, China, Hong Kong, USA, Canada	[94]
28	-	-	rs2947349	C	-	0.28	1 x 10–8	1.23 (1.16–1.31)
29	MMP8	Proteinase	rs1939012	T	-	0.385184	2 x 10–8	1.02 (1.07–1.17)
30	PCDH7	Cell adhesion molecule	rs1044352	G	-	0.473243	2 x 10–7	1.14 (1.08–1.22)
31	-	-	rs55670112	C	-	0.474441	6 x 10–8	0.47 (1.10–1.26)
CAE
32	CACNA1H	Calcium channel gene	rs9934839	G	R603R	0.396565	<0.0001	-	China	[31]
			rs2745150	T	-	0.090256	<0.0001	-
			rs8044363	C	-	0.332668	0.0242	-		[25]
			rs8043905	A	-	0.330871	0.015	-
			rs9934839	G	R603R	0.3966	0.012	3.367 (1.307–8.671)
			rs3751664	T	-	0.046725	0.025	1.760 (1.074– 2.886)
			c.937A>G	G	M313V	-	0.01	0.070 (0.008–0.619)
			rs119454947	A	F161L	0	-	-		[30,32]
			rs119454949	A	V831M	0.00002	-	-
33	CACNG3	Calcium channel gene	rs447292-rs4787924-rs2239341-rs1494550-c-597delT- rs965830-rs2214437-rs2238500 and rs4787924, rs965830, rs2214437	A, G, A, T, T, G, A	-	0.348442, 0.46865, 0.277356, 0.240815, 0.470847, 0.470647, 0.427316	<0.005	-	UK, France, Germany, Austria, the Netherlands, Denmark, Sweden, Finland and Italy	[26]
34	CHRNA4	Acetylcholine receptor	CfoI bp595	T	-	-	0.0397	3.57 (1.16–11.02)	Germany	[52]
35	GRM4	Glutamate receptor	rs2499697	C	-	0.92	0.0021	2.36 (1.34–4.15)	Germany	[51]
			rs2451357	G	-	0.87	0.0466	-
36	GABRA1	GABA A receptor	rs1581220270	c.975del	-	-	-	-	Germany	[95]
37	GABRB3	GABA A receptor	rs25409	T	P11S	0.002	-	-	Mexico	[46]
38	GABRG2	GABA A receptor	rs1561645243	G	-	-	-	-	Germany	[96]
39	JRK/JH8	Nucleic acid binding	Thr456Met	456Met	T456M	-	-	-	France, Switzerland, Italy and the UK	[97]
40	LGI4	Leucine-rich repeat LGI	c.1914GC-AT	GC/GC	-	-	0.024	2.57 (1.24–5.33)	Germany, Belgium, Turkey	[62]
41	OPRM1	Opioid receptor	rs1799971	G	N40D	0.2234	0.019	2.03 (1.12–3.68)	Germany	[57]
42	SCL6A3/DAT1	Transporter	40 base pair VNTR polymorphism	Nine-copy allele	-	-	0.002	2.258 (1.32–3.85)	Germany	[59]
43	VRK2, ACTG1P22	Vaccinia-related kinase	rs12185644	C	-	0.35643	5 x 10–10	-	Caucasian, Asian and African-American	[13]
44	ZEB2	Zfh1	rs13020210	G	-	0.311302	2 x 10–8	-
JME
45	BRD2	Nucleic acid binding	rs3918149	A	-	0.161542	0.043	1.93(1.01–3.70)	Ireland	[98]
			rs3918149	A	-	0.161542	0.001	2.63(1.42–4.87)	UK
			rs3918149	A	-	0.161542	-	2.8(1.19–6.64)	North America	[99]
			rs516535	G	-	0.390775	-	2.05(1.00–4.22)
			rs635688	T	-	0.390775	-	2.16(1.05–4.42)
			rs206674	G	-	0.003994	-	2.51(1.20–5.24)
			rs206787	-	-	0.390575	-	2.21(1.08–4.52)
			rs3918149	A	-	0.161542	-	2.8(1.19–6.64)
			rs206777	G	-	0.369409	-	2.29(1.11–4.71)
			rs497058	T	-	0.389776	-	2.08(1.01–4.28)
46	CHRNA4	Acetylcholine receptor	rs45442394	T	-	0.021166	0.029	1.914 (1.057–3.467)	Poland	[100]
47	CACNB4	Calcium channel gene	R482X	T	R482X	<0.006	-	-	United state	[101]
48	CTF1	Serum cardiotrophin-1	rs1046276	T	-	0.4113	3 × 10–11	-	Europe	[13]
49	CHRM3	Cholinergic receptor	rs12059546	G	-	0.3298	4.1 × 10–8	1.42	Europe	[89]
50	CILK1	Kinase	rs376111440	T	R632	0.000032 (GnomAD)	-	-	United States, Mexico, Honduras, Brazil and Japan	[102]
			rs55932059	A	A615T	0 (ALFA)	-	-
			rs1554169267	G	K220E		-	-
			rs765078446	C	K305T	0.000033	-	-
51	CX36	Connexin	rs3743123	TT	S196S	0.308906	0.0195	1.62(1.02–2.57)	Germany	[103]
			rs3743123	TT	S196S	0.308906	0.017	4.3 (1.5–12.3)	UK, Denmark, France, Greece, Portugal and Sweden	[104]
52	EFHC1	Signal transduction molecule	rs137852778	T	D234Y	0.00002	-	-	Japan	[105]
			rs137852776	C	F229L	0.0018	-	-
			rs137852777	A	D210N	0.000058	-	-
			rs149055334	A	P77T	0.002349	-	-
			rs79761183	A	R221H	0.009585	-	-
53	EFHC2	Signal transduction molecule	rs2208592)	T	S430Y	0.085298	0.03	2.17 (1.06–4.43)	Germany	[106]
54	GABRA1	GABA A receptor	rs121434579	-	A322D	-	-	-	Canada	[107]
55	GRM4	Glutamate receptor	rs9380405	T	-	0.310304	0.0106	1.33 (1.07–1.65)	Germany	[51]
			rs4711374	T	-	0.301717	0.0266	-
			rs1466650	T	-	0.404153	0.042	-
			rs11753413	T	-	-	0.0294	-
			rs2029461	G	-	0.402157	0.0204	-
			rs2029461	AG	-	0.402157	0.005	1.641 (1.238–2.175)	India	[108]
			rs2029461-rs2451334-rs745501-rs2499697-rs937039	ACAAA	-	0.402157, 0.163339, 0.330471, 0.0784747 0.257987	<0.0001	0.4907 (0.3475–0.6927)
				ACACA	-		0.00047	2.5490 (1.5119–4.2973)
				ATAAG	-		<0.0001	4.8533 (2.2672–10.3895)
				GCACA	-		0.004525	0.4125 (0.227–0.7495)
56	KCNJ10	Potassium channel gene	rs1130183	T	R271C	0.014776	0.011	0.59 (0.37–0.95)	Germany	[85]
57	KCNQ2	Potassium channel gene	rs1801545	C	-	0.069286	0.022	-	Germany	[74]
58	hSKCa3	Potassium channel gene	polyglutamine CAG tract	CAG16	-	-	0.018	1.198	South India	[77]
				CAG18	-	-	0.019	1.178
				CAG19	-	-	<0.00001	0.514
59	HLA	HLA complex	HLA-DRB1*1301-1302	DRB1* 1301-1302	-	-	<0.017	6.6	USA	[109]
			HLA-DQB1*0603-0604	DQB1* 0603-0604	-	-	<0.005	13.8
			HLA-DQ1	DQ1	-	-	<0.01	-	Japan	[110]
			HLA-DQ3	DQ3	-	-	<0.02	-
			HLA_DRW13	DRW13	-	-	0.002	4.85 (1.70–14.0)	Saudi Arabia	[111]
60	SLC2A1	Transporter	rs387907313	T	R232C	0.000008	-	-	Italy	[93]
61	TAP-1	Transporter	333Val-637Asp	-	333V-637D	-	0.007	2.61 (1.27–5.33)	France	[112]
		Transporter	333Ile-637Gly	-	333I-637G	-	0.02	2.30 (1.11–4.77)
		Transporter	333Val-637Asp	-	333V-637D	-	0.04	0.4	Tunisia	[92]
		Transporter	333Ile-637Asp	-	333I-637D	-	0.03	6.36
62	STX1B	Membrane trafficking	rs1046276	T	-	0.411342	3 × 10–11	-	Finland, USA, Australia, Canada, Belgium, UK, Republic of Ireland, China, Hong Kong, Canada	[13]
JAE
63	INHA	-	rs7588807	G	-	0.4722	-	-	Turkey	[113]
TLE
64	APOE	Apolipoproteins	ApoE-epsilon-4	epsilon4	-	-	0.004	-	Australia	[114]
			ApoE-epsilon-4	epsilon4	-	-	>0.05	1.06 (0.38–2.95)	Turkish	[115]
65	ASC1a	Sodium channel	rs844347	A	-	0.224641	0.004	1.516 (1.142–2.013)	China	[116]
			rs844347	A	-	0.224641	0.002	1.628 (1.193–2.222)
66	ALDH5A1	Enzyme	rs1883415	C	-	0.289537	0.0019	-	Germany	[117]
67	AQP4	Water channel	ss119336753, ss119336754 and rs1058424	-	-	0.228834	<0.05	-	Norway	[118]
68	BDNF	Nucleic acid binding	rs6265	A	V66M (M66 protective)	0.201278	0.012	1.21 (1.04–1.41)	China	[119]
			rs6265	A	V66M (M66 protective)	0.201278	0.636	0.636	Brazil (Caucasian, African, African descent, Asian)	[120]
			rs6265	A	V66M (M66 protective)	0.201278	0.355	-	Europe	[121]
			C240T	T	S80I	-	0.022	-	Japan	[13]
69	CALHM1	Calcium channel	rs2986017	A	-	0.128	0.072	1.37 (0.96–1.96)	China	[122]
			rs11191692	A	-	0.298522	0.003	1.35 (1.103–1.653)	China	[123]
			rs11191692–rs729211–rs2986016–rs2986017	G, G, G, T	-	0.298522, 0.363618, 0.119808, 0.127995	0.0029	2.09 (1.27–3.42)
			rs11191692–rs729211–rs2986016–rs2986017	G, A, G, C	-	0.298522, 0.363618, 0.119808, 0.127995	0.0106	0.7 (0.53–0.92)
70	C3	Immune	Dinucleotide (CA) repeat	-	-	-	<0.05	-	Spain	[124]
71	CPA6	Enzyme	rs114402678	T	A270V	0.00359	-	-	Morocco	[125]
			rs61738009	A	G267R	0.001398	-	-
72	GABBR1	GABA A receptor	G1465A	A/G	-	-	<000.1	-	Italy	[126]
			G1465A (with drug-resistant TLE)	A	-	-	0.003	6.47 (2.02–20.76)
			G1465A	A/G	-	-	<0.0001	10.01 (3.98–25.18)	Argentina	[127]
73	GABRB3	GABA A receptor	rs4906902	-	-	0.199681	0.5498		Germany	[117]
74	GABBR2	GABA A receptor	rs967932	A	-	0.157149	0.018	1.305 (1.048–1.624)	China	[128]
75	GAL	Galanin	C116A	-	A39E	-	-	-	Geneva	[129]
76	5-HTR2A	Serotonin receptor	rs6314	T	-	0.074681	0.006	-	Italy	[130]
77	5-HTTVNTR	Serotonin receptor	10-repeat allele	-	-	-	0.0187	1.55 (1.07–2.26)	China	[131]
78	5-HT1A	Serotonin receptor	rs6295	C	-	0.45	0.048	2.77 (1.01–7.63)	Brazil	[132]
79	5HT-1B	Serotonin receptor	rs6296/G861C	G	-	0.33	0.0385	1.574 (1.031–2.402)	Croatia	[129]
80	5-HTTVNTR	Serotonin receptor	-	-	-	-	0.0145	RR= 0.21 (0.07–0.65)	Croatia	[133]
81	IL-1α	Signaling molecule	rs1800587/IL-1α–889 allele	A	-	0.278	0.018	-	Europe (Caucasian)	[134]
82	KEAP1	Kelch-like ECH-associated protein 1	rs1048290	G	-	0.491813	0.04	0.41 (0.20–0.84)	China	[135]
83	KCNAB1	Potassium channel gene	rs2280032	A	-	0.479233	0.028	1.84 (1.07–3.18)	Italy	[136]
		Potassium channel gene	rs992353	C	-	0.459265	0.0058	2.25 (1.26–4.04)
84	KCNAB2	Potassium channel gene	rs1386956-rs9816126-rs728382-rs4679773-rs9876870-rs3755631-rs2280561-rs1546750-rs17352408-rs2720281-rs429513-rs2280299-rs2280032-rs992353	GGGGCCTGGGGTTG		0.30611, 0.344249, 0.401358, 0.483826, 0.421326, 0.216653, 0.433706, 0.382987, 0.228634, 0.464058, 0.307308, 0.479233, 0.459265	0.028	12.24 (1.32–113.05)	Italy	[136]
85	KCNJ10	Potassium channel gene	rs17375748	-	-	0.024	0.025	-	Norway	[118]
			rs1186685	-	-	0.1829	0.009	-
			rs4656873	-	-	0.1787	0.019	-
			rs1186679	-	-	0.1759	0.021	-
			rs1890532	-	-	0.1905	0.041	-
			rs946420	-	-	0.1771	0.024	-
			rs2820585	-	-	0.1771	0.02	-
86	NTRK2	Receptor	rs10868235	T	-	0.351837	0.01	1.9 (1.17–3.09)	Brazil	[137]
87	NRG1	Signaling molecule	rs35753505	C	-	-	0.026	0.082 (0.082 (0.009–0.746))	China	[138]
88	NFE2L2	Basic leucine zipper (bZIP) proteins	rs7557529–rs35652124–rs6706649–rs6721961–rs2886161– rs1806649–rs2001350–rs10183914–rs2706110	A, A, G, C, A, G, A, G, G	-	0.395168, 0.375599, 0.1451, 0.063299, 0.33631,0.105232, 0.128, 0.23, 0.331669	0.03	7.11 (1.53–32.98)	China	[135]
			rs2706110	A	-	0.331669	0.03	1.95 (1.06–3.58)
89	PDYN	Signaling molecule	-	L-allele	-	-	0.005	-	Austria	[139]
			-	L-allele	-	-	0.061	-	Italy	[140]
			-	L- allele	-	-	0.163	1.6 (0.82–3.31)	Europe (Caucasian)	[134]
90	PRNP	Prion protein	rs1799990	G	M129V	0.266	0.021	2.527 (1.11–5.75)	Italy	[141]
			Asn171Ser	-	N171S		<0.0001		Brazil	[107]
91	TLR4	Receptor	rs4986790	G	-	0.059904	0.512	1.964 (0.176–21.90)	Europe (Caucasian)	[142]
92	t-PA	Tissue plasminogen activator	rs2020918	T	-	-	0.006	2.008 (1.223–3.298)	China	[143]
			rs4646972	311 bp deletion	-	-	0.000	2.007 (1.418–2.840)	China
93	SCN1A	Sodium channel gene	rs7587026	A	-	0.212061	4 × 10–8	1.24 (1.15–1.34)	Finland, USA, Belgium, UK, Switzerland, Austria, Republic of Ireland, Australia, Italy, the Netherlands, Portugal, Germany	[144]
			rs3812718	T	-	0.493411	0.0001	1.67 (1.28–2.16)	South India	[76]

Table 1 provides the genetic basis of common epilepsies. There is genetic heterogeneity among these epilepsies. In other words, the same phenotype is caused by variants of different genes. For example, CAE is caused by genes encoding the γ2 and α subunits of γ-aminobutyric acid (GABA_A) receptors GABRG2, GABRA1, and calcium voltage-gated channel subunit alpha 1 H CACNA1H and other genetic variants of different genes mentioned in table. These observations illustrate the genetic complexity of the inherited epilepsies and may provide valuable new information for reassessing their classification. In this table, we listed the genes/variants significantly associated with common epilepsy subtypes as well as with GGE as whole obtained from the literature. GGE: genetic generalized epilepsy; CAE: Childhood absence epilepsy; JME: juvenile myoclonic epilepsy; JAE: Juvenile absence epilepsy; TLE: Temporal lobe epilepsy.

Table 1. Overview of the common epilepsyassociated genetic variants.

Sl. No.	Gene/Loci	Gene Family	SNP/Genetic Variant	Risk Allele	Protein Change	GMAF	p-Value	OR (CI)	Country	Reference
GGE
1	SLC4A3	Solute carrier transporter family	2600G/A	A	A867D	-	0.021	1.48 (1.03–2.14)	Germany	[75]
2	CACNA1A	Calcium channel	SNP 8 (SNP in exon 8)	A	-	-	0.00033	1.8 (1.3–2.4)	USA	[76]
3	CHRNA4	Acetylcholine receptor	rs1044396	T	S543S	0.323	0.0126	4.9 (1.71–14.04)	Taiwan	[77]
			rs1044394	T	-	0.136	0.02	3.57 (1.31–9.72)	Germany	[52]
4	D18S474 locus/18q12	-	-	D18S474 8- and 9-	-	-	<0.001	-	Italy	[78]
5	GABRA6	GABA A receptor	rs3219151	T	-	0.43112	<0.001	3.6 (2.1–5.9)	South India	[79]
6	GABARG	GABA A receptor	rs211037	T	-	0.371605	0.004	7.36	Egypt	[80]
7	GRIK	Glutamate receptor	GRIK tetra-nucleotide polymorphism	9 repeat allele	-	-	0.004	1.26 (1.08–1.47)	Germany	[81]
8	GRM4	Glutamate receptor	rs9380405	T	-	0.69	0.003	-	Germany	[51]
			rs937039	G	-	0.257987	0.0038	-
			rs2451334	A	-	0.163339	0.0118	-
			rs2029461-rs2451334-rs745501-rs2499697-rs937039	TGTAA	-	0.402157,0.163339,0.330471, 0.078474, 0.25798	0.0069	3.54 (1.42–8.83)	Jordan	[82]
9	Haptoglobin (Hp)	-	Hp*1	Hp*1	-	-	<0.001 (Hp*1/*1 vs. other types of epilepsy vs. controls in individuals containing *B/*B genotype in ACP1	0.72 (0.011–0.58)	Italy	[83]
10	KCNJ3	Potassium channel gene	T1038C	T	-	-	0.051	1.4 (1.0–1.9)	UK	[84]
11	KCNJ10	Potassium channel gene	rs1130183	C	R271C	0.014776	0.03	0.69 (0.50–0.95)	Germany	[85]
12	KCNMB3	Potassium channel gene	delA750	-	-	-	0.016	1.52 (1.05–2.21)	Germany	[86]
13	KCNQ2	Potassium channel gene	rs1801545	C		0.069286	0.01	1.62 (1.12–2.34)	Germany	[74]
14	KCNQ3	Potassium channel gene	rs74582884	A	P574S	0.0015	0.008	-	India
15	ME2	Enzyme	rs674351- rs584087 - rs585344 - rs608781 - rs642698 - rs674210 - rs645088 - rs649224 - rs654136	A-A-C-A-G-A-C-C-A	-	0.287141, 0.269169, 0.270168, 0.164736, 0.260783, 0.270767, 0.272364, 0.15615	-	6.1 (2.9–12.7)	New York	[87]
16	MTHFR	Methylene tetrahydrofolate reductase	rs1801133/677C>T	T	A222V	0.24	0.01	2.26 (1.13–4.5)	Scotland	[88]
17	COPZ2	Coatomer subunit zeta-2	rs72823592	A	-	0.103834	9.3 × 10–9	0.77 (0.71–0.83)	Austria, Belgium, Denmark, Germany and the Netherlands	[89]
18	SCN1A	Sodium channel gene	rs8191987	G	-	0.225439	0.03	-	UK	[90]
			rs16851381	G	-	0.166134	0.05	-
			rs2298771	G	-	0.2115	0.002	-
19	SCN2A	Sodium channel gene	rs2060199	A	-	0.53	0.04	-
			rs935403	-	-	-	0.03	-
			rs3943809	G	-	0.202	0.04	-
20	SCN8A	Sodium channel gene	rs303777	A	-	0.297724	0.007	-
21	SLC12A5	Transporter	c.3145 C > T	T	R1049C	-	0.044	9.61 (0.8–503.6)	Canada	[91]
22	SYN II	Membrane trafficking	rs37733634	-	-	-	<0.001	2.57 (2.0–3.2)	South India	[79]
			rs3773364	G	-	0.269968	0.02	1.55 (1.06–2.26)	North India	[87]
23	TAP-1A	Transporter	333Val-637Asp	-	333V-637D	-	0.02	0.47	Tunisia	[92]
24	TAP-1C	Transporter	333Ile-637Asp	-	333I-637D	-	0.03	4.3
25	VAMP2	Vesicle-associated membrane protein (VAMP)/synaptobrevin family	26 bp Ins/Del	ins/del*	-	-	0.042	0.474 (0.230–0.978)	Turkey	[93]
26	SYT11	Synaptotagmin XI	33-bp repeats in promoter region	C	-	-	<0.001	2.317 (1.503–3.573)
27	VRK2	Vesicle-associated membrane protein (VAMP)/synaptobrevin family	rs13026414	T	-	0.224641	2.5 × 10–8	-	Finland, USA, Australia, Canada, Belgium, UK, Republic of Ireland, China, Hong Kong, USA, Canada	[94]
28	-	-	rs2947349	C	-	0.28	1 x 10–8	1.23 (1.16–1.31)
29	MMP8	Proteinase	rs1939012	T	-	0.385184	2 x 10–8	1.02 (1.07–1.17)
30	PCDH7	Cell adhesion molecule	rs1044352	G	-	0.473243	2 x 10–7	1.14 (1.08–1.22)
31	-	-	rs55670112	C	-	0.474441	6 x 10–8	0.47 (1.10–1.26)
CAE
32	CACNA1H	Calcium channel gene	rs9934839	G	R603R	0.396565	<0.0001	-	China	[31]
			rs2745150	T	-	0.090256	<0.0001	-
			rs8044363	C	-	0.332668	0.0242	-		[25]
			rs8043905	A	-	0.330871	0.015	-
			rs9934839	G	R603R	0.3966	0.012	3.367 (1.307–8.671)
			rs3751664	T	-	0.046725	0.025	1.760 (1.074– 2.886)
			c.937A>G	G	M313V	-	0.01	0.070 (0.008–0.619)
			rs119454947	A	F161L	0	-	-		[30,32]
			rs119454949	A	V831M	0.00002	-	-
33	CACNG3	Calcium channel gene	rs447292-rs4787924-rs2239341-rs1494550-c-597delT- rs965830-rs2214437-rs2238500 and rs4787924, rs965830, rs2214437	A, G, A, T, T, G, A	-	0.348442, 0.46865, 0.277356, 0.240815, 0.470847, 0.470647, 0.427316	<0.005	-	UK, France, Germany, Austria, the Netherlands, Denmark, Sweden, Finland and Italy	[26]
34	CHRNA4	Acetylcholine receptor	CfoI bp595	T	-	-	0.0397	3.57 (1.16–11.02)	Germany	[52]
35	GRM4	Glutamate receptor	rs2499697	C	-	0.92	0.0021	2.36 (1.34–4.15)	Germany	[51]
			rs2451357	G	-	0.87	0.0466	-
36	GABRA1	GABA A receptor	rs1581220270	c.975del	-	-	-	-	Germany	[95]
37	GABRB3	GABA A receptor	rs25409	T	P11S	0.002	-	-	Mexico	[46]
38	GABRG2	GABA A receptor	rs1561645243	G	-	-	-	-	Germany	[96]
39	JRK/JH8	Nucleic acid binding	Thr456Met	456Met	T456M	-	-	-	France, Switzerland, Italy and the UK	[97]
40	LGI4	Leucine-rich repeat LGI	c.1914GC-AT	GC/GC	-	-	0.024	2.57 (1.24–5.33)	Germany, Belgium, Turkey	[62]
41	OPRM1	Opioid receptor	rs1799971	G	N40D	0.2234	0.019	2.03 (1.12–3.68)	Germany	[57]
42	SCL6A3/DAT1	Transporter	40 base pair VNTR polymorphism	Nine-copy allele	-	-	0.002	2.258 (1.32–3.85)	Germany	[59]
43	VRK2, ACTG1P22	Vaccinia-related kinase	rs12185644	C	-	0.35643	5 x 10–10	-	Caucasian, Asian and African-American	[13]
44	ZEB2	Zfh1	rs13020210	G	-	0.311302	2 x 10–8	-
JME
45	BRD2	Nucleic acid binding	rs3918149	A	-	0.161542	0.043	1.93(1.01–3.70)	Ireland	[98]
			rs3918149	A	-	0.161542	0.001	2.63(1.42–4.87)	UK
			rs3918149	A	-	0.161542	-	2.8(1.19–6.64)	North America	[99]
			rs516535	G	-	0.390775	-	2.05(1.00–4.22)
			rs635688	T	-	0.390775	-	2.16(1.05–4.42)
			rs206674	G	-	0.003994	-	2.51(1.20–5.24)
			rs206787	-	-	0.390575	-	2.21(1.08–4.52)
			rs3918149	A	-	0.161542	-	2.8(1.19–6.64)
			rs206777	G	-	0.369409	-	2.29(1.11–4.71)
			rs497058	T	-	0.389776	-	2.08(1.01–4.28)
46	CHRNA4	Acetylcholine receptor	rs45442394	T	-	0.021166	0.029	1.914 (1.057–3.467)	Poland	[100]
47	CACNB4	Calcium channel gene	R482X	T	R482X	<0.006	-	-	United state	[101]
48	CTF1	Serum cardiotrophin-1	rs1046276	T	-	0.4113	3 × 10–11	-	Europe	[13]
49	CHRM3	Cholinergic receptor	rs12059546	G	-	0.3298	4.1 × 10–8	1.42	Europe	[89]
50	CILK1	Kinase	rs376111440	T	R632	0.000032 (GnomAD)	-	-	United States, Mexico, Honduras, Brazil and Japan	[102]
			rs55932059	A	A615T	0 (ALFA)	-	-
			rs1554169267	G	K220E		-	-
			rs765078446	C	K305T	0.000033	-	-
51	CX36	Connexin	rs3743123	TT	S196S	0.308906	0.0195	1.62(1.02–2.57)	Germany	[103]
			rs3743123	TT	S196S	0.308906	0.017	4.3 (1.5–12.3)	UK, Denmark, France, Greece, Portugal and Sweden	[104]
52	EFHC1	Signal transduction molecule	rs137852778	T	D234Y	0.00002	-	-	Japan	[105]
			rs137852776	C	F229L	0.0018	-	-
			rs137852777	A	D210N	0.000058	-	-
			rs149055334	A	P77T	0.002349	-	-
			rs79761183	A	R221H	0.009585	-	-
53	EFHC2	Signal transduction molecule	rs2208592)	T	S430Y	0.085298	0.03	2.17 (1.06–4.43)	Germany	[106]
54	GABRA1	GABA A receptor	rs121434579	-	A322D	-	-	-	Canada	[107]
55	GRM4	Glutamate receptor	rs9380405	T	-	0.310304	0.0106	1.33 (1.07–1.65)	Germany	[51]
			rs4711374	T	-	0.301717	0.0266	-
			rs1466650	T	-	0.404153	0.042	-
			rs11753413	T	-	-	0.0294	-
			rs2029461	G	-	0.402157	0.0204	-
			rs2029461	AG	-	0.402157	0.005	1.641 (1.238–2.175)	India	[108]
			rs2029461-rs2451334-rs745501-rs2499697-rs937039	ACAAA	-	0.402157, 0.163339, 0.330471, 0.0784747 0.257987	<0.0001	0.4907 (0.3475–0.6927)
				ACACA	-		0.00047	2.5490 (1.5119–4.2973)
				ATAAG	-		<0.0001	4.8533 (2.2672–10.3895)
				GCACA	-		0.004525	0.4125 (0.227–0.7495)
56	KCNJ10	Potassium channel gene	rs1130183	T	R271C	0.014776	0.011	0.59 (0.37–0.95)	Germany	[85]
57	KCNQ2	Potassium channel gene	rs1801545	C	-	0.069286	0.022	-	Germany	[74]
58	hSKCa3	Potassium channel gene	polyglutamine CAG tract	CAG16	-	-	0.018	1.198	South India	[77]
				CAG18	-	-	0.019	1.178
				CAG19	-	-	<0.00001	0.514
59	HLA	HLA complex	HLA-DRB1*1301-1302	DRB1* 1301-1302	-	-	<0.017	6.6	USA	[109]
			HLA-DQB1*0603-0604	DQB1* 0603-0604	-	-	<0.005	13.8
			HLA-DQ1	DQ1	-	-	<0.01	-	Japan	[110]
			HLA-DQ3	DQ3	-	-	<0.02	-
			HLA_DRW13	DRW13	-	-	0.002	4.85 (1.70–14.0)	Saudi Arabia	[111]
60	SLC2A1	Transporter	rs387907313	T	R232C	0.000008	-	-	Italy	[93]
61	TAP-1	Transporter	333Val-637Asp	-	333V-637D	-	0.007	2.61 (1.27–5.33)	France	[112]
		Transporter	333Ile-637Gly	-	333I-637G	-	0.02	2.30 (1.11–4.77)
		Transporter	333Val-637Asp	-	333V-637D	-	0.04	0.4	Tunisia	[92]
		Transporter	333Ile-637Asp	-	333I-637D	-	0.03	6.36
62	STX1B	Membrane trafficking	rs1046276	T	-	0.411342	3 × 10–11	-	Finland, USA, Australia, Canada, Belgium, UK, Republic of Ireland, China, Hong Kong, Canada	[13]
JAE
63	INHA	-	rs7588807	G	-	0.4722	-	-	Turkey	[113]
TLE
64	APOE	Apolipoproteins	ApoE-epsilon-4	epsilon4	-	-	0.004	-	Australia	[114]
			ApoE-epsilon-4	epsilon4	-	-	>0.05	1.06 (0.38–2.95)	Turkish	[115]
65	ASC1a	Sodium channel	rs844347	A	-	0.224641	0.004	1.516 (1.142–2.013)	China	[116]
			rs844347	A	-	0.224641	0.002	1.628 (1.193–2.222)
66	ALDH5A1	Enzyme	rs1883415	C	-	0.289537	0.0019	-	Germany	[117]
67	AQP4	Water channel	ss119336753, ss119336754 and rs1058424	-	-	0.228834	<0.05	-	Norway	[118]
68	BDNF	Nucleic acid binding	rs6265	A	V66M (M66 protective)	0.201278	0.012	1.21 (1.04–1.41)	China	[119]
			rs6265	A	V66M (M66 protective)	0.201278	0.636	0.636	Brazil (Caucasian, African, African descent, Asian)	[120]
			rs6265	A	V66M (M66 protective)	0.201278	0.355	-	Europe	[121]
			C240T	T	S80I	-	0.022	-	Japan	[13]
69	CALHM1	Calcium channel	rs2986017	A	-	0.128	0.072	1.37 (0.96–1.96)	China	[122]
			rs11191692	A	-	0.298522	0.003	1.35 (1.103–1.653)	China	[123]
			rs11191692–rs729211–rs2986016–rs2986017	G, G, G, T	-	0.298522, 0.363618, 0.119808, 0.127995	0.0029	2.09 (1.27–3.42)
			rs11191692–rs729211–rs2986016–rs2986017	G, A, G, C	-	0.298522, 0.363618, 0.119808, 0.127995	0.0106	0.7 (0.53–0.92)
70	C3	Immune	Dinucleotide (CA) repeat	-	-	-	<0.05	-	Spain	[124]
71	CPA6	Enzyme	rs114402678	T	A270V	0.00359	-	-	Morocco	[125]
			rs61738009	A	G267R	0.001398	-	-
72	GABBR1	GABA A receptor	G1465A	A/G	-	-	<000.1	-	Italy	[126]
			G1465A (with drug-resistant TLE)	A	-	-	0.003	6.47 (2.02–20.76)
			G1465A	A/G	-	-	<0.0001	10.01 (3.98–25.18)	Argentina	[127]
73	GABRB3	GABA A receptor	rs4906902	-	-	0.199681	0.5498		Germany	[117]
74	GABBR2	GABA A receptor	rs967932	A	-	0.157149	0.018	1.305 (1.048–1.624)	China	[128]
75	GAL	Galanin	C116A	-	A39E	-	-	-	Geneva	[129]
76	5-HTR2A	Serotonin receptor	rs6314	T	-	0.074681	0.006	-	Italy	[130]
77	5-HTTVNTR	Serotonin receptor	10-repeat allele	-	-	-	0.0187	1.55 (1.07–2.26)	China	[131]
78	5-HT1A	Serotonin receptor	rs6295	C	-	0.45	0.048	2.77 (1.01–7.63)	Brazil	[132]
79	5HT-1B	Serotonin receptor	rs6296/G861C	G	-	0.33	0.0385	1.574 (1.031–2.402)	Croatia	[129]
80	5-HTTVNTR	Serotonin receptor	-	-	-	-	0.0145	RR= 0.21 (0.07–0.65)	Croatia	[133]
81	IL-1α	Signaling molecule	rs1800587/IL-1α–889 allele	A	-	0.278	0.018	-	Europe (Caucasian)	[134]
82	KEAP1	Kelch-like ECH-associated protein 1	rs1048290	G	-	0.491813	0.04	0.41 (0.20–0.84)	China	[135]
83	KCNAB1	Potassium channel gene	rs2280032	A	-	0.479233	0.028	1.84 (1.07–3.18)	Italy	[136]
		Potassium channel gene	rs992353	C	-	0.459265	0.0058	2.25 (1.26–4.04)
84	KCNAB2	Potassium channel gene	rs1386956-rs9816126-rs728382-rs4679773-rs9876870-rs3755631-rs2280561-rs1546750-rs17352408-rs2720281-rs429513-rs2280299-rs2280032-rs992353	GGGGCCTGGGGTTG		0.30611, 0.344249, 0.401358, 0.483826, 0.421326, 0.216653, 0.433706, 0.382987, 0.228634, 0.464058, 0.307308, 0.479233, 0.459265	0.028	12.24 (1.32–113.05)	Italy	[136]
85	KCNJ10	Potassium channel gene	rs17375748	-	-	0.024	0.025	-	Norway	[118]
			rs1186685	-	-	0.1829	0.009	-
			rs4656873	-	-	0.1787	0.019	-
			rs1186679	-	-	0.1759	0.021	-
			rs1890532	-	-	0.1905	0.041	-
			rs946420	-	-	0.1771	0.024	-
			rs2820585	-	-	0.1771	0.02	-
86	NTRK2	Receptor	rs10868235	T	-	0.351837	0.01	1.9 (1.17–3.09)	Brazil	[137]
87	NRG1	Signaling molecule	rs35753505	C	-	-	0.026	0.082 (0.082 (0.009–0.746))	China	[138]
88	NFE2L2	Basic leucine zipper (bZIP) proteins	rs7557529–rs35652124–rs6706649–rs6721961–rs2886161– rs1806649–rs2001350–rs10183914–rs2706110	A, A, G, C, A, G, A, G, G	-	0.395168, 0.375599, 0.1451, 0.063299, 0.33631,0.105232, 0.128, 0.23, 0.331669	0.03	7.11 (1.53–32.98)	China	[135]
			rs2706110	A	-	0.331669	0.03	1.95 (1.06–3.58)
89	PDYN	Signaling molecule	-	L-allele	-	-	0.005	-	Austria	[139]
			-	L-allele	-	-	0.061	-	Italy	[140]
			-	L- allele	-	-	0.163	1.6 (0.82–3.31)	Europe (Caucasian)	[134]
90	PRNP	Prion protein	rs1799990	G	M129V	0.266	0.021	2.527 (1.11–5.75)	Italy	[141]
			Asn171Ser	-	N171S		<0.0001		Brazil	[107]
91	TLR4	Receptor	rs4986790	G	-	0.059904	0.512	1.964 (0.176–21.90)	Europe (Caucasian)	[142]
92	t-PA	Tissue plasminogen activator	rs2020918	T	-	-	0.006	2.008 (1.223–3.298)	China	[143]
			rs4646972	311 bp deletion	-	-	0.000	2.007 (1.418–2.840)	China
93	SCN1A	Sodium channel gene	rs7587026	A	-	0.212061	4 × 10–8	1.24 (1.15–1.34)	Finland, USA, Belgium, UK, Switzerland, Austria, Republic of Ireland, Australia, Italy, the Netherlands, Portugal, Germany	[144]
			rs3812718	T	-	0.493411	0.0001	1.67 (1.28–2.16)	South India	[76]

Table 1 provides the genetic basis of common epilepsies. There is genetic heterogeneity among these epilepsies. In other words, the same phenotype is caused by variants of different genes. For example, CAE is caused by genes encoding the γ2 and α subunits of γ-aminobutyric acid (GABA_A) receptors GABRG2, GABRA1, and calcium voltage-gated channel subunit alpha 1 H CACNA1H and other genetic variants of different genes mentioned in table. These observations illustrate the genetic complexity of the inherited epilepsies and may provide valuable new information for reassessing their classification. In this table, we listed the genes/variants significantly associated with common epilepsy subtypes as well as with GGE as whole obtained from the literature. GGE: genetic generalized epilepsy; CAE: Childhood absence epilepsy; JME: juvenile myoclonic epilepsy; JAE: Juvenile absence epilepsy; TLE: Temporal lobe epilepsy.

Signal Transduction Molecule

The EF-hand-containing calcium binding protein encoded by EFHC1 gene, which mediate signaling at the synapse in cooperation with a EFHC1-interaction partner, R-type voltage-dependent calcium channels (VDCC) and has apoptotic activity [145]. Loucks CM et al. demonstrated in C. elegans, that EFHC1 functions within specialized non-motile mechano-sensory cilia where it modulate mechanosensitive calcium channels and at dopaminergic synapse which play a role in neurotransmitter release and thus regulates neuronal excitation Thus, it suggests that EFHC1 protein regulate excitation both at the cilium and at the synapse [146]. This gene is involved in various neuronal functions like regulation of cell division, apoptosis, ion channels, neuronal migration, neurite architecture and neurotransmitter release [73,147] Suzuki et al. observed that in vivo disruption of EFHC1 gene in mice leads to myoclonus seizures and increases seizure susceptibility [105]. Genetic variants like P77T (rs149055334) and R221H (rs79761183) lessen the apoptotic activity of the gene leading to an increase in neuronal cell count and precarious calcium homeostasis by partial reversal of EFHC1-induced Ca2+ influx through CaV2.3 [145]. Reports showed increased density and dystopia of neuron in the brains of JME patients [148]. The combined effect of these result in hyper-stimulation of neurons which give rise to seizure development and JME [145,149]. However in CaV2.3 deficit mice models, no seizure phenotype has been described which may be due to undetected seizure sensitivity [150].

Nucleic Acid Binding

Bromo-domain containing 2 (BRD2) gene encodes nuclear transcriptional regulator, that belongs to bromo-domains and extra-terminal domain family of proteins which bind specifically to acetylated histones H3 and H4 [151]. These are expressed in developing neural tissue [152]. BRD2 deficit mouse model developed neural tube closure defects and alteration in BRD2 expression during neurodevelopment which may result in increased susceptibility to seizures [153]. BRD2 heterozygous mice showed JME-like behavioral trait, sex specific seizure threshold and seizure related anatomical changes in GABAergic system [154], supporting BRD2 involvement in JME. The genetic variant, rs3918149 within the C-phosphate-G dinucleotides (CpG) island 76 of the BRD2 promoter region was revealed to be an epigenetic variant significantly associated with JME in the Caucasian population. Authors discussed that patients with JME show CpG76 hyper-methylation, possibly leading to decrease in BRD2 transcription [67,99,155]. In an animal model study, BRD2-null mutation (BRD2+/−) in mice causes a decrease in GABAergic neurons along the basal ganglia seizure-controlling pathway and GABA-synthesizing enzyme expression (GAD67), increasing seizure susceptibility and seizure development. This in turn might result in decrease in specific GABAergic neuronal population and enhanced seizure susceptibility [99,154,155]. Variation in promoter may disrupt interaction with other proteins involved in controlling particular stages of brain development. Neural cell overgrowth or lack of apoptosis in specific regions of the brain may occur due to abnormalities in development pathway. These abnormalities result in unorganized neuronal connectivity causing hyper-excitability which leads to seizure development, a mechanism of epileptogenesis [99,149]. Though supporting evidence for BRD2 association with JME was found in British and Irish cohort, no such association was seen in Australian, German and Southern Indian population [98]. Non-Caucasian population failed to support BRD2 association with JME [112,156]. All these evidences suggest that BRD2 in JME, is ethnicity specific, showing differential methylation.

GABA A Receptor

GABRA1 gene was initially implicated in familial JME [157]. Mutations in the GABAAR such as Q351X (rs121909674), R43Q (rs121909673) in GABRG2, A322D (rs121434579), S326fs328X in GABRA1, and R220H (rs41307846) in GABRD are majorly involved in reduced protein expression of GABAAR [158]. In vitro studies suggest that A322D missense mutation causes α1 protein mis-folding, due to which α1 subunit is rapidly degraded in endoplasmic reticulum through the ubiquitin–proteasome system [159]. This lowers surface expression of mature protein [160], in turn reducing GABA evoked chloride currents, leading to neuronal disinhibition by preventing hyperpolarization of membrane [161]. Studies have shown that R220H variant of GABRD can be a susceptibility allele for JME [162,163]. In contrast, Lenzen et al. found no association between the R220H variant and JME among 562 German patients and 664 controls [164].

So far, ten GWAS studies have been carried out for epilepsy in general, and two studies found SNPs association with JME. First stage GWAS study of EPICURE included 586 patients with JME and 2461 controls of North Western European ancestry and replication stage included 382 European JME patients with 382 ethnically matched controls. After combined association analysis of both the stages, rs12059546 in M3 muscarinic acetylcholine receptor (CHRM3), reached genome-wide significance [89]. Studies suggested CHRM3 gene to play a role in differential cholinergic modulation in distinct hippocampal cell, which may influence synchronization and excitability of thalamo-cortical circuits and thereby seizure susceptibility [165]. However the results were proved inconclusive in a pilocarpine model [166]. Another genome-wide mega-analysis that included 15,212 people with epilepsy and 29,677 controls, found a significant association of rs1046276 (STX1B) at 16p11.2 locus with JME [13]. This gene has a role in release of neurotransmitter by fusion of presynaptic vesicle membrane [167]. Variant in STX1B may result in hyper-excitability of neuron giving rise to epilepsy [168].

2.1.3. Juvenile Absence Epilepsy (JAE) and Epilepsy with Generalized Tonic–Clonic Seizures (EGTCS)

JAE is a GGE syndrome typically begins between 10 and 16 years of age with a peak at 15 years [169] and is predominantly characterized by absence seizures. Patients may experience other seizure types as GTCS, GTCS on awakening, and myoclonic seizures also. Exact etiology of JAE is not known, but studies have shown genetic variations in genes like voltage-gated sodium channels (CACNB4), ligand-gated ion channels (GABRA1, GRIK1) and EFHC1 genes to be involved in JAE [170]. Sander et al. reported an allelic association with GLU R5 kainate receptor gene (GRIK1 polymorphism), which has a role in excitatory neurotransmission [81]. Another association study revealed a strong association of a common intronic SNP (rs7588807) in the inhibin alpha precursor gene (INHA) with JAE [113]. INHA encodes inhibin protein, which inhibits the secretion of follicle-stimulating hormone (FSH), in turn inducing the production of progesterone and estradiol. This SNP is predicted to exert a direct effect by increasing the brain excitability or an indirect effect on absence seizures as increased production of progesterone enhances slow wave discharge through allo-pregnanolone, a positive modulator of GABAAR [171].

EGTCS commences at 10 to 16 years of age in which GTCS that occur mostly within 2 h after awakening from sleep, hence also known as epilepsy with tonic-clonic seizures on awakening. The genetics of EGTCS is complex. No genetic variants are found linked with EGTCS [172]. Some studies have reported JAE and EGTCS as common epilepsies [173] but role of genetics in their etiology is highly elusive. Hence, we have not discussed these epilepsies in detail.

2.2. Temporal Lobe Epilepsy (TLE)

TLE is most common form of partial epilepsy which is often associated with brain injury, head stroke, trauma and infection. Hence, it is classified under symptomatic or structural epilepsy. Based on the seizure origin, TLE is subdivided as mesial, lateral and neocortical. Genetic factors along with other factors like injury, infection or lesions in temporal lobe, are also believed to be involved in its etiology. Hence, to understand the role of genetics in TLE, linkage analysis in families and association studies have been carried out [137,174]. Studies have suggested that LGI1 mutations is linked with autosomal dominant lateral temporal lobe epilepsy. These studies showed that family members of affected person are at high risk than members of healthy individuals.

2.2.1. Sodium Ion Channels

It is one of the most important class of genes associated with various epilepsy phenotypes [175]. The voltage-gated sodium ion channels consist of large α subunits that associate with β subunits to form voltage gated ion channels [176]. There are several alleles of the alpha subunit gene referred to as SCN1A through SCN11A. Based on the sequence, expression profile and kinetics, sodium channels are distinguished. SCN1A variants are found associated with a continuum of epilepsy phenotypes such as intractable childhood epilepsy with generalized tonic-clonic seizures, including simple febrile seizures or familial fever-related epilepsies referred to as generalized epilepsies with febrile seizures and also a risk factor for common epilepsies like TLE and GGE [177]. A meta-analysis revealed genome-wide significant association of an intronic polymorphism i.e. rs7587026 of SCN1A for mesial temporal lobe epilepsy with hippocampal sclerosis with febrile seizures [144]. Another intronic variant rs3812718 is also found significantly associated with mesial temporal lobe epilepsy with hippocampal sclerosis [76]. This polymorphism disrupt the conserved consensus-site sequence and result in weaker 5’ splice site which increase the expression of exon 5N. Product of this transcript variant of SCN1A cause altered electrical signaling [178].

2.2.2. Calcium Homeostasis Modulator 1 (CALHM1)

Calcium channel encoding gene CALHM1 has a role in calcium-dependent neuronal signaling [179]. Calcium ions have a substantial role in epilepsy development [180]. A polymorphism rs2986017 in this gene interferes with calcium homeostasis and increases amyloid β levels [181]. Experimental data have suggested that overexpression of amyloid β in the brain can cause epileptiform activity and can increase intra-neuronal resting Ca2+ concentration [182] and seizure susceptibility [183]. Increased amyloid β levels in the form of senile plaques have been observed in TLE patients [184]. Another polymorphism in the 3’ UTR of same gene rs11191692 was identified as a risk factor for TLE subjects in North China. This SNP might affect Ca2+ mediated release of excitatory neurotransmitter and also modulates amyloid beta level though precise mechanism is yet to be identified [123]. In vitro studies suggested role of Ca2+ ions in TLE [185] and increased amyloid β level causes aberrant neuronal activity resulting in cortical and hippocampal network susceptible for epilepsy [186]. A replication study in TLE patients from South China failed to support previous finding that CALHM1 contribute substantially to MTLE [122]. Failure to replicate previous studies may be due to underpowered sample size and undetected population stratification. Hence, it is possible that initial finding gave a true association with MTLE [186].

2.2.3. γ- Aminobutyric Acid B Receptor 1 (GABBR1)

An essential component of pre- and postsynaptic GABABR, encoded by GABBR1, is abundantly expressed in temporal lobe structures. This ligand-gated GABABR inhibits release of neurotransmitter from presynaptic neurons and mediates late inhibitory postsynaptic potentials [187]. A missense mutation in exon 7 of GABBR1, c.1465G>A (p.Gly489Ser) was found significantly associated with TLE [126]. In another study subjects carrying heterozygous A allele for this polymorphism had 10 fold increase in risk for MTLE with hippocampal sclerosis [127]. This genetic variant is present in N-terminal extracellular domain of the GABABR, which is the site for ligand binding. Hence, this genetic polymorphism may affect the ligand binding properties which may perturb correct functioning of receptor that would lead to inhibition of GABA release from pre-synapse and promote development of seizures. The association of this genetic variant with TLE did not replicate in other studies and remained inconclusive [128,188,189,190,191,192,193]. A positive association was found for the A-allele of rs967932 (GABBR2) with the risk of TLE in the Chinese population. These patients showed frequent occurrence of GABBR2 haplotype (G-C-A-C, rs3780428-rs1999501-rs967932-rs944688, respectively) predisposing them to the early onset of the disease [128]. The role of this haplotype is not clear.

2.2.4. Aquaporin

The aquaporin 4 (AQP4) gene encode a protein that acts as water selective channel. AQP4 expression in glial cell (astrocyte) has a role in water and ion homeostasis in brain, as water flux through this channel, is coupled with extracellular K+ clearance through inwardly rectifying K+ channel [194]. In vivo studies have shown that deletion of AQP4 perturb the osmolarity by accumulation of K+, which causes membrane depolarization resulting into synchronous discharge from nerve cells and increase seizure susceptibility [195,196]. Interestingly, AQP4 expression is reduced in the kainate model of epilepsy, and this is also confirmed in AQP4 deficit mice in which seizure susceptibility is increased. This reduced expression of AQP4 might impair water delivery to the extracellular space and increase excitability [197,198]. Eid T. et al. also found that perturbed expression pattern of AQP4 and its anchoring complex in MTLE patients, could underlie the deficiency in water and K+ homeostasis [199]. Heuser et al. indicated three non-coding variants in AQP4 in significant association with TLE [118]. These variants might act as regulatory element and decrease the expression pattern of AQP4.

2.2.5. Serotonin Transporter (5-HTT)

Serotonin neurotransmitter has a substantial role in cortical and subcortical excitatory/inhibitory balance. After its release from pre-synapse, its action is terminated by its reuptake via 5-HTT which is key regulator in serotoninergic neurotransmission and has anticonvulsant property [200]. Two functional polymorphisms of 5-HTT, 5-HTTLPR (an insertion/deletion in 5 UTR) and 5-HTTVNTR (a VNTR in intron 2) were suggested to modulate its transcription and play a role in TLE etiology. Deletion of 44 bp in promoter region generates a 14-repeat variant and its insertion generates a 16-repeat allele in the 5-HTTLPR which are known as short (S, low expressing) and long (L, high expressing) alleles respectively. A significant association for lower frequency of 10 repeat allele at 5-HTTVNTR in TLE patient was found but no association was observed for 5-HTTLPR [133]. A study shown that MTLE-HS homozygous carrier of 12 repeat allele of 5-HTTVNTR had higher risk for non-response to medical treatment compared to 10 repeat allele carrier [201]. Combination of the transcriptionally more efficient 5-HTT genotypes, i.e., 5-HTTLPR L/L and VNTR-2 12/12 was found to be associated with poor response of optimal drug therapy [202]. In contrast to these findings, an association was found between transcriptionally less efficient combined genotypes of 5-HTTLPR and 5-HTTVNTR and TLE [203]. Li et al. found a higher frequency of 10-repeat allele at 5-HTTVNTR whereas Chi et al. found association of 12/12 genotype and allele 12 at 5-HTTVNTR in Han Chinese TLE subjects [131,204]. Stefulj et al. did not find any association between 5-HTTLPR or 5-HTTVNTR and TLE but a high frequency of serotonin receptor 5HT-1B allele 861G was found in the TLE patients of the Croatian population [205].

2.2.6. Prodynorphin (PDYN)

Prodynorphin (PDYN) gene encodes the precursor of anticonvulsant dynorphin opioid peptides. A 68bp tandem repeat element containing binding site for AP-1 transcription factor, is present in the core promoter of PDYN gene, and regulate its expression [206]. This polymorphism causes low expression of this gene. AP-1 has a central role in regulation of seizure-related gene expression by affecting transcriptional machinery. One or two repeats of 68bp named as L-allele, is associated with low PDYN expression, resulting in low prodynorphin level which increase susceptibility for epilepsy. Whereas the H-allele, characterized by three or four repeats of the element is associated with high expression of PDYN gene, causing anti-convulsive effect. Two studies found L-allele to increase the risk of TLE in patients with familial history of seizures [139,140]. This result was not replicated in four independent studies of the Caucasian population for TLE [134,188,207,208]. However, a meta-analysis suggested that the L-allele variant of this promoter polymorphism might contribute as a risk factor for familial-TLE suggesting that further studies are required for acquiring discrete results [209].

2.2.7. Acid-Sensing Ion Channel Subunit 1 (ASIC1)

Acid sensing ion channel subunit 1alpha (ASIC1a) gene encodes a member of the acid-sensing ion channel (ASIC) family of proteins widely expressed in the neurons of the peripheral sensory and the central nervous system [210]. In vitro and in vivo studies indicate that ASIC1a get activated by low extracellular pH value in brain followed by high expression of ASIC1a in hippocampal astrocytes of TLE patients and epileptic mice [211,212].This causes a significant increase of intracellular Ca2+ ion level in astrocytes. Accumulation of Ca2+ ions activates astrocytes to release glio-transmitter like glutamate which promote generation and spread of seizures [213]. On the contrary, Ziemann et al. reported that ASIC1a is highly expressed in GABAergic interneurons which is involved in termination of seizure [214]. The seizure generation and termination depends on the excess expression of ASIC1a on active astrocytes or GABAergic neuron, respectively [213]. A genetic association study in the Han Chinese population showed that rs844347 in the intronic region of ASIC1a gene could be a plausible risk factor for TLE [116].

2.2.8. Apolipoprotein E (ApoE)

The gene, ApoE encoding a major apoprotein of the chylomicron, has three major isoforms: ApoEε2, ApoEε3 and ApoEε4. Earlier reports on ApoEε4 association with early onset TLE subjects of Italy was not significant [215]. Later the same allele was found positively associated with early onset TLE subjects in the Australian population [114]. Subsequently, five replication studies in different populations were performed [115,134,188,216,217] but one study suggested association with TLE [134]. Another study reported that ApoEε4 allele in intractable TLE affect both verbal and non-verbal memory performance [218] and increases the risk of post-ictal confusion [219]. While Kauffman et al. did not find any association with the same [220]. A study in the Han Chinese population suggest that ApoEε4 allele is involved in development of TLE in patients with prior brain trauma [221] and is a risk factor for non-lesional MTLE [222]. All these evidences suggest that ApoEε4 allele has a role in TLE. ApoEε4 contributed substantially in neuronal degeneration through promoting intracerebral accumulation of β-amyloid [223], which act as a linker between ApoEε4 and TLE [224]. Kodam A et al. also demonstrated increased production or secretion of amyloid beta related peptides from activated astrocytes to cause neurotoxicity suggesting these peptides have a role in TLE pathogenesis [225].

2.2.9. Neurotrophic Receptor Tyrosine Kinase 2 (NTRK2)

The NTRK2 gene encodes a membrane receptor kinase TrkB [226] that undergoes auto-phosphorylation upon binding of neuron survival factor neurotrophin. TrkB plays an essential role in maintaining synaptic plasticity. Reduction in TrkB receptor expression or its inactivation has been demonstrated to impair seizure induction and epileptogenesis in various in vivo studies. Torres CM et al. performed a case-control study to compare the allelic/genotypic frequencies of multiple polymorphisms of TRKB gene between Caucasian patients with TLE and healthy controls. An increasing statistical trend for T/T genotype of rs10868235 was observed in patient group. Further, analyzing clinical or electrographic variables in the patient group revealed that the patients with A/A genotype for rs1443445 had early age at seizure onset. Also, patients in need of polytherapy had a greater frequency of T-allele for rs3780645 than patients on monotherapy [137].

2.3. Cryptogenic Focal Epilepsy (CFE)

Epilepsy which do not meet the criteria of idiopathic/ genetic partial epilepsy and also lack underlying genetic, structural or metabolic etiology is known as cryptogenic focal epilepsy. This epilepsy type does not have a clear etiology hence also known as unknown epilepsy and accounts for a significant proportion of all epilepsies [227]. Harkin et al., identified de novo mutation in SCN1A gene in 22% of CFE patient cohort [228]. Another study of SCN1A confirmed the findings of first study having 12.5% of CFE patients with SCN1A variation [229]. Beside this, no other genes have been found associated with CFE.

3. Genetic Burden of Rare and Common Variants in Common Epilepsies

The most important unresolved question in genetics of epilepsy is, if the genes responsible for rare/monogenic epilepsy also contribute to common epilepsies and to what extent. Another concern is, if the rare variants with large effect size and/or common variants with minimal odds ratio contribute to the common epilepsy disease risk [229,230]. To find the burden of ultra-rare (allele frequencies < 0.0005) genetic variation in common epilepsies, WES was performed coordinated by the Epi4K Consortium. Findings of this study suggested that DEP (Dishevelled, Egl-10 and Pleckstrin) domain containing 5 (DEPDC5), leucine-rich glioma inactivated 1 (LGI1), protocadherin 19 (PCDH19), SCN1A, and glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) are the five genes which occupied the top genome-wide ranks in order of increasing p-value in individuals with familial non-acquired focal epilepsy. Out of these only DEPDC5 gene showed genome-wide significance. But none of the genes were significant for GGE cases. However, potassium voltage-gated channel subfamily Q member 2 (KCNQ2), SCN1A, and GABRG2 are three established genes among top ten genes for common epilepsies [231]. Independent studies confirmed that pathogenic variants in such genes are ultra-rare in general population and are present not more than once in 60,000 individuals in population database like ExAC [232]. Another study by EuroEPINOMICS consortium found enrichment of rare variants with minor allele frequencies <0.005 in GABAAR encoding 19 genes in GGE patients but did not identify genome-wide burden of rare variants in single gene [233]. To yield more significant result the largest whole exome sequencing was performed for 17,606 individuals by EPI25 consortium. This study found that across all three classes of epilepsy like severe developmental and epileptic encephalopathies, GGE and non-acquired focal epilepsy, gene GABRG2 were enriched for missense variants. GABAergic inhibition plays an important role in epilepsy etiology. The findings of this study also suggest a higher genetic burden of ultra-rare variants on GGE than non-acquired focal epilepsy [234]. All these evidences show that rare variants contribute to common epilepsies.

Common variants that contributes to common epilepsies have so far yielded mostly non-reproducible results. Nonetheless, with the inclusion of larger sample cohorts and use of polygenic risk score studies made better attempt in investigating the attributable common variants with higher statistical rigor. A meta-analysis of GWAS identified two genes SCN1A and protocadherin7 (PCDH7) common for all epilepsies i.e. GGE, focal epilepsy and unknown. Another locus 2p16.1 was found significantly associated with all GGEs, but it was uncertain which of the genes in this loci, VRK2 or FANCL gene, play a role in the same [94]. Association of this locus was also strengthened by one GWAS study and another mega analysis [94]. The VRK2 gene encode a protein kinase involved in signal transduction and apoptosis. This locus (2q24.3) was found to be associated with both GGE and focal epilepsy in two different mega analyses [13,94]. Identification of large number of significant risk allele has become possible due to increasing sample size and through large collaborative work [13]. Common risk variants associated with a disease cannot individually quantify risk because these variants generally have a small effect size [235].

However, polygenic risk score (PRS) can be used to estimate the cumulative effect of thousands of variants into a single score, rather than considering single variant effect in disease as in GWAS. The PRS can be used to distinguish patients with epilepsy (based on severity), individuals who are at risk of developing epilepsy and healthy individuals [236]. This approach highlighted that common variants collectively explain 26% phenotypic variation for all epilepies, 27% for focal epilepsy and, approximately 33% for GGE [13,237]. The estimated contribution of common risk variants obtained by this method is greater than any other analytical method supporting the hypothesis that multiple genes contribute to common epilepsies [238]. Leu et al. calculated the PRS from the GWAS for two main subtype of epilepsy: GGE and focal epilepsy and observed that generalized epilepsy have a significantly higher burden of common risk variants than patients with focal epilepsy [236]. It is also observed that there should be homogeneity between the population from which PRS is calculated and the population on which it is applied, otherwise it results into low predictive power of PRS [239].

Extensive research is required to generate new prediction model to exploit the use of PRS by distinct cohorts from different populations with well-characterized epilepsy phenotypes. A combined risk score including PRS along with weighted scoring of non-genetic risk factors will be the most accurate method for implementing it in clinical practice. This will prove a boon for clinicians as well as for patients in better prognosis and precision treatment. Non-genetic risk factors include individual characteristics (diet, sex, life stage, ethnicity, education), the clinical factors (severity, age at onset, treatment gap, available treatments, comorbidities), community context and values (religion, social networks, support, personal preferences, economic strata), internal milieu of an individual (epigenetic, microbiome profile and metabolome), brain infections and environmental factors, which influence the genetic information and epilepsy risk, hence cannot be neglected [240,241]. In the context of epilepsy, a link between gut microbiome and brain through gut-brain axis have also been established through neuro-immuno-endocrine mediators [242]. This combined scoring of genetic and non-genetic factors will make a paradigm shift from risk prediction and clinical management for rare monogenic epilepsies to complex epilepsies and also help in filling the gap of precision medicine for common epilepsies

4. Copy Number Variants (CNVs) in Epilepsy

Apart from SNPs, CNVs have been demonstrated as risk or causal genetic markers in GGE including both in JME and CAE. Development of chromosome microarray and SNP genotyping arrays facilitated genome-wide screening for de-novo CNVs in large cohorts [243]. The first CNV identified was 15q13.3 microdeletion in CHRNA7 is linked with intellectual disability and epilepsy [243]. Sharp et al. described this microdeletion recurrence in people with epilepsy or individuals showing abnormal EEG. CHRNA7 coding for synaptic ion channel protein is important for neuronal signal transmission and has been previously shown to be susceptibility factor for JME and benign epilepsy of childhood. In vivo data also shows its involvement in hyper-synchronous EEG phenotype. Study in the subsequent year also found 15q13.3 microdeletion encompassing the CHRNA7 gene in patients with IGE, supporting role of 15q13.3 microdeletion as a prevalent genetic risk factor for epilepsy. Dibbens et al. further confirmed GGE to be the most frequent phenotype associated with the 15q13.3 microdeletion. With the odd ratio of 68, the deletion indicated any pathogenic lesion predisposing to epilepsy with polygenic inheritance and incomplete penetrance in GGE [244,245]. High density SNP array unveiled microdeletions at 15q11.2 and 16p13.11 to be significantly involved in epileptogenesis in patients with GGE [246]. These three microdeletions are represented as “genetic hotspot” as they share a common genetic architecture. 15q13.3, 15q11.2 and 16p13.11 deletions are primarily risk factors for GGE and also found in patients with focal epilepsy (

Table 2. Different copy number variants (CNVs) associated with epilepsies.

Sl. No.	Locus	Size	CNVs	Gene		Phenotype	Consequences	Country	Year	References
1	2p16.3	~287 and ~79 kb	Exon-disrupting deletion		Nrxn1	Severe early onset epilepsy	Alteration in the calcium-dependent release of neurotransmitters	UK	2011 (case report)	[251]
2	2q24.2-q24.3	11Mb	Duplication/deletion		SCN1A, SCN2A, SLC4A10	Idiopathic epilepsy	Imbalance in sodium channel	Brazil	2010 (case report)	[252]
3	6p12.1	99.9kb	Micro-duplication		BMP5	Epilepsy	Increased cell death in ventral forebrain	Saudi Arabia	2015	[253]
4	7q11.22	78.7kb	Deletion		AUTS2	JME	Role in neurodevelopment	Switzerland, Germany, USA	2010	[254]
5	7q32.3	63.9kb	Microdeletion		PODXL	Epilepsy	Malignant progression of astrocytic tumors	Saudi Arabia	2015	[253]
6	7q35	785.8kb	Deletion, hemizygous deletions		CNTNAP2	GTCS	Affects cell–cell interaction in nervous system	Switzerland, Germany, USA	2010	[254]
7	15q11.2		Microdeletion		NIPA2, CYFIP1	GGE	Role in neuronal growth and differentiation	Austria, Belgium, Denmark, Germany, the Netherlands	2010	[246]
8	15q13.3	1.4Mb	Microdeletion		CHRNA7	GGE (specifically JME)	Modulates thalamo-cortical pathways	Switzerland, Germany, USA	2009, 2010	[244,254]
9	16p13.11	800Kb	Deletion		NDE1	MTLE	Brain structural alterations	UK	2012	[255]
10	16p13.2	47Kb	Microdeletion		GRIN2A	RE (childhood epilepsy)	Disrupt GRIN2A	France	2014	[256]
11	22q11.2	3Mb	Microdeletion		DGCR6, DGCR6L	GGE (specifically JME)	Haplo-insufficiency of DGCR6 in 22q11 could disturb interaction with GABABR	The Netherlands	2016	[257]

). A study including 315 patients with epileptic encephalopathy did not find any of these microdeletions highlighting the fact that common epilepsies have a different genetic architecture than epileptic encephalopathies [247]. Rare exonic deletions in neuronal genes as neuronal adhesion molecule of pre-synaptic terminal i.e. neurexin 1 (NRXN1) [248], neuron specific splicing regulator gene, RNA binding fox-1 homolog 1(RBFOX1) [249], and scaffolding protein in the neuronal post synaptic membrane gephyrin (GPHN) [250] disrupt the exons and are also found to increase the risk of GGE.

5. Clinical Implication and Relevance of Genetic Findings

Remarkable advancements in identifying the causative mutations and technological growth in epilepsy genetics have channelized genetic testing into clinics. Various systemic level biomarker can be used to ensure proper diagnosis of the disease and the prediction of the treatment outcome (prognosis of anti-epileptic drug response) (Figure 3). Genetic biomarker is used to predict the risk occurrence of epilepsy in a person with a family history of epilepsy which is a commonly encountered situation. This can be used for pharmaco-response for selected antiepileptic drugs. Performing testing of specific single gene for diagnostics is no longer a practical approach for complex diseases like common epilepsies. Thus, development of gene panels and beginning of NGS-based or exome sequencing platforms for disease diagnosis has marked its way for a more comprehensive assessment of the disease status. These platforms predict the putative pathogenic variants of genes having a role in specific epilepsy subtype, and also of those genes with no known evidences with disease, but might regulate other genes with known functions in epilepsy. This may help us investigate the potential pathogenicity of such variants. Such studies hint that along with genetic data, clinical phenotyping, family history/ genealogy data together can assist in precision medicine in epilepsy. Clinical phenotyping does not include only neurological examination and tests but also thorough assessment of seizure type, duration and frequency, dysmorphic features, cutaneous signs, congenital malformation, variable symptoms of any other organ or organ system impairment, results of radiological, biochemical and other testing, cognitive functioning information etc. These phenotypes are influenced by several genes, epigenetic and environmental factors. Hence, gene/variant interpretation are crucially dependent on the full phenotypic picture of the patient. Therefore, these genetic variants need to be analyzed and integrated with detailed clinical phenotyping to make a diagnosis. These changes will make improvements in diagnosis and treatment.

Beyond efficient prognosis or diagnosis of the disease, one of the other prime intent behind performing genetic studies is to identify novel evidence-based drug targets for future drug development. It may also allow better designing of clinical trials to standardize drug dosing, treatment outcome evaluation or toxicity profiling with respect to specific phenotypic spectrum. Given the genetic complexity of epilepsy, different genes cause specific epilepsy subtypes that are clinically indistinguishable and on the other hand, monogenic SNPs like in SCN1A cause varied phenotypes, from febrile seizure to epileptic encephalopathies. Therefore, this is the right time to proceed towards precision medicine in epilepsy. Apart from reducing the seizure frequency alone, a panoramic view of the disease mechanism with other factors like effect of common and rare variants, CNVs, polygenic risk evidences, pathways network, pharmacogenomics, other clinical phenotypes like neuro-images, EEG patterns, facilitate headway to precision medicine.

5.1. Prognosis

Variations in epilepsy genes generate variability in seizure type, epilepsy type, severities and other comorbidities. These variabilities may be due to single gene or a genetic variant (Figure 4). Genotyping along with deep phenotyping is essential in this genomic era. Genetic marker- specific prognosis is explored for rare epilepsy syndrome and is expanding for common epilepsies. It can render the diagnosis more certain in an early stage of the disease. For e.g. variations in KCNQ2 and KCNQ3 having 85% penetrance are identified as causal factor of benign familial neonatal seizures [258,259]. Genetic variants in such genes decrease the threshold membrane depolarization and increase neuronal burst [260]. Therefore, identification of variants in these genes with clinical phenotyping specific to benign familial neonatal seizures have a good prognosis, and can aid patient to get rid of seizures and medications at an early stage. But genetic variants in same genes cannot act as good biomarker for prognosis in all epileptic encephalopathy patient. In benign familial neonatal–infantile seizures patients, dominant point mutation is found in SCN2A gene, encode the alpha-subunit of the voltage-gated sodium channel NaV1.2 [261]. This point mutation results in increased neuronal excitability by gain of function [262,263]. Non-sense mutation found in the same gene result in more severe epilepsy and/or epilepsy encephalopathy, leading to a bad outcome. Thus, genetics can assist in outcome prediction in the benign familial epilepsies of childhood.

5.2. Diagnosis

Genetic insights into the disease have given a new direction to epilepsy diagnoses directly affecting clinical care. It not only controls seizure frequency but also improves neurodevelopmental comorbidities associated with the disease. It has the prospect of wider dispersal once new targeted treatments continue to emerge based on genetic evidences. Precision diagnostics is not new in the clinical management of epilepsies which follow Mendelian inheritance but progress to genetic analysis in common epilepsies is impeded by complex pattern of inheritance. However, limited findings of candidate gene studies and GWAS have suggested role of common variants in epilepsy, nonetheless all these are causal genes/variants necessarily be susceptible to disease risk. A genetic diagnosis is very important for disease management as it avoids the unnecessary repeated blood tests, invasive biopsies, MRIs, pre-surgical workup, and even unnecessary implementation of intracranial electrodes for monitoring electrical activity of seizure. Genetic diagnosis along with the family history is very helpful in estimating the epilepsy risk for other family members that are to be tested [264]. For example, studies have shown that polymorphisms in CACNA1H gene [25,265] GABAA receptor gene with variation γ2(R43Q, rs121909673) [39], β3(P11S; rs25409), β3(S15F; rs121913126), β3(G32R; rs71651682) [46], α1(S326fs328X) [95], GABRG2(IVS6 + 2T→G) [96], GABRB3 haplotype 2 are associated with CAE and these genes are commercially used for CAE genetic testing. Commercially available genetic testing is focused on gene panels that comprises individual gene, group of genes or chromosomal loci diagnosis a specific epileptic trait. Such tests exploit the advanced NGS platforms like whole genome sequencing, NGS or targeted sequencing or others. Targeted sequencing is used for identifying genetic variants in individual gene when specific epilepsy is suspected. Epilepsy gene panel involves the analysis of group of most common genes associated with discrete epilepsy sub-types. Advantage of using gene panel is that it covers all possible genetic cause of epilepsy. Chromosome microarray involves analysis of chromosome to check any imbalance that may cause epilepsy. Endo-phenotype markers along with genetics could be useful to dissect disease complexity. Imaging endo-phenotypes and genetics provide a link between brain features and underlying genetic architecture to facilitate identification of disease related genetic variants. For e.g., photo-peroxisomal EEG response is a common observation in JME and can be a useful endo-phenotype in epilepsy gene mapping. Candidate gene studies showed association of photo-peroxisomal EEG response with BRD2 gene in JME share some neurological pathways [266]. Motor system hyper-activation and impairment of memory is observed in JME patients and their siblings, implicating trait heritability and a JME endo-phenotype [267]. Alterations of temporal cortical surface area, absence of shared thickness abnormalities and varying patterns of hippocampal atrophy is detected in family studies of TLE patients [268]. Nowadays, machine learning through neuroimaging data (resting state functional MRI, diffusion tensor imaging is being used to find specific patterns in epilepsy, enabling seizure prediction, and to distinguish between active epilepsy patient and seizure free patient. Further, using clinical data, machine learning can also predict medical and surgical outcomes through using clinical data. One assessment of a support vector machine classifier revealed a peak diagnostic sensitivity of 82.5% and a specificity of 85% by evaluating the asymmetry of functional connectivity in homologous brain regions on resting-state functional MRI in 100 patients with epilepsy and 80 controls. These endo-phenotype studies will compliment for disease category phenotype studies [269,270]. There are number of genetic tests for rare epilepsies compared to common epilepsies. The genes available for genetic testing for common epilepsies are listed below in

Table 3. List of available genetic diagnosis markers for common epilepsies.

Sl. No.	Gene	Genomic Loci	Putative Markers	Gene Function	Phenotype Prediction	Company	Major Ethnic Group
1	SLC2A1	1p34.2	-	Solute carrier transporter	Genetic generalized epilepsy	Centogene AG the Rare Disease Company and Blueprint Genetics	European
2	CACNB4	2q23.3	-	Voltage-gated calcium channel
3	GABRG2	5q34	-	GABA receptor	Generalized epilepsy with febrile seizures plus	Invitae, GeneDx, Fulgent Genetics, LifeLabs Genetics, Laboratoria de Genetica Clinica SL, Institute of Human Genetics and Cologne University	American and European
4	STX1B	16p11.2	-	Synaptic vesicle
5	SCN1A	2q24.3	rs8191987, rs16851381, rs2298771	Voltage-dependent sodium channel
6	SCN1B	19q13.11		Voltage-gated sodium channel
7	SCN9A	2q24.3		Voltage-gated sodium channel
8	GABRA1	5q34	rs1581220270	GABA receptor	Childhood absence epilepsy	Invitae, LifeLabs Genetics and Clinical Molecular Genetics Laboratory	American
9	GABRB3	15q12	rs25409	Ligand-gated ionic channel
10	GABRG2	5q34	rs1561645243	GABA receptor
11	JRK	8q24.3	T456M	DNA-binding protein
12	CACNA1H	16p13.3	rs9934839, rs2745150, rs8044363, rs8043905, rs9934839, rs3751664, c.937A>G, rs119454947, rs119454949	Voltage-dependent calcium channel
13	CACNB4	2q23.3	R482X	Voltage-dependent calcium channel	Juvenile myoclonic epilepsy	Athena Diagnostics Inc, GeneDx, Invitae, MedGen and Illumina Clinical Services Laboratory	American & European
14	EFHC1	6p12.2	rs137852778, rs137852776, rs137852777, rs149055334, rs79761183	Calcium-binding protein
15	GABRA1	5q34	rs121434579	GABA receptor
16	CILK1	6p12.1	rs376111440, rs55932059, rs1554169267, rs765078446	Protein kinases
17	GAL	11q13.2	C116A	Galanin and GMAP prepropeptide	Familial temporal lobe epilepsy	Invitae, GeneDx, Fulgent Genetics, LifeLabs Genetics, Laboratoria de Genetica Clinica SL, Institute of Human Genetics, Cologne University, Athena Diagnostics Inc, CGC Genetics, MNG Laboratories (Medical Neurogenetics, LLC), PreventionGenetics, Amplexa Genetics	American & European
18	CPA6	8q13.2	rs114402678, rs61738009	Metallocarboxypeptidases
19	RELN	7q22.1	-	Cell–cell interaction
20	LGI1	10q23.33	-	-
21	MICAL1	6q21	-	Depolymerization of actin filaments

In this table, we have mentioned the genes that are used for genetic testing by different testing companies. These genes are obtained from the Genetic Testing Registry (GTR).

(Supplementary Table S1) and for rare epilepsies are listed in Supplementary Table S2. Although making genetic diagnostics available to every patient is still critical and challenging. Several attempts made so far in the field of epilepsy genetic could be potential candidates that requires rigorous testing to prove safety and efficacy and demands appropriate functional validation before it is used for assessment in the clinic. Based on the literature evidence, diagnostic efficacy like sensitivity, specificity and positive predictive values are calculated for genetic variants are given in

Table 4. Genetic marker for genetic testing in epilepsy with diagnostic efficacy.

Sl No	Gene	Variant	Location	Risk Allele	GMAF	Phenotype	Sample Size (P/C)	Country	Study (PMID)	Sensitivity	Specificity	PPV	OR
1.	Cx36	rs3743123	Coding	T	0.401	JME	169/123	UK, Denmark, France, Greece, Portugal, and Sweden	15235036	37.8	70.7	37.4	1.4
							247/621	Germany	16876983
2.	SCN1A	rs3812718	Intronic	A	0.581	Epilepsy	76/701	Australia	19949041	56.6	47.6	39.4	1.2
							90/701		19289736
							97/837	China	20477842
							362/86	India	20602612
							62/199	Switzerland	21762453
							138/282	India	22578703
							234/189	Taiwan	22188362
							485/298	India	23466530
							133/209	Austria	24014518
							212/344	German
							282/470	Malaysian Chinese	25668517
							151/244	India
							243/358	Malaysia
							200/200	Greece	28144265
3.	GABRG2	rs211037	Coding	T	0.222	Epilepsy	135/154	Germany	12117362	32.6	45.1	38.5	0.6
							53/96	Italy	12694927
							104/83	Taiwan	12672902
							94/106	Japan	12759178
							569/330	British	16806831
							684/284	Ireland
							74/118	America	16256272
							77/83	Taiwan	17162195
							100/120	Egypt	21983990
							441/267	India	24061200
							60/153	Roman	29379546
							100/100	Brazil	23287319
							1719/4672	Malaysia, Hong Kong, Korea, India	26452361
4	BRD2	rs3918149	5′ UTR	A	0.246	JME	531/1390	Britain, Iran, Germany, Australia, India	17437413	17	13	27.4	1.14
							116/470	Germany	30719712
5	CACNA1H	rs9934839	Coding	G	0.340	CAE	100/191	China	16905256	9.17	5.49	65.6	1.73
							218/191	China	17156077

GMAF: Global minor allele frequency.

. These can be potential genetic markers for epilepsy testing.

5.3. Pharmacogenomics

The aim of pharmacogenomics is to predict how different individuals respond when prescribed with the same drug (and its dose). This aids in better clinical management of epilepsy by reducing adverse drug response and improving drug efficacy. Based on several such evidences, the USA food and drug administration (FDA) has approved drug labelling for patients with certain genetic variants. Most of them are addressed to reduce life-threatening adverse drug response. For e.g., the carriers of the rare POLG1 nucleotide substitution (p.Q1236H) may develop fatal hepatic failure when treated with sodium valproate [271]. A prospective genetic testing of such carrier patients may help clinicians identify individuals at high risk of this fatal drug toxicity. In other cases, one of the most widely studied HLA allele variant (HLA-B*15:02) predispose patients to a severe skin hypersensitivity (Stevens-Johnson syndrome/ toxic epidermal necrolysis) reaction when treated with carbamazepine [272]. It was investigated in Han Chinese population, and few other ethnic populations of Southeast Asian origin. On the contrary, HLA-A*3101 allele seemed to confer the risk of carbamazepine induced skin ADR in white people of northern Europe [273]. According to an alert from US FDA, Carbamazepine should be avoided if patients carry at least one copy of HLA-B*15:02 allele and if patients are having carbamazepine for few months and do not show any cutaneous reaction then such patients are at low risk of developing such reaction ever from carbamazepine FDA Alert [12/12/2007]. Hence, alternate drugs are recommended for patients with HLA-B*15:02 or HLA-A*3101 allele [274]. Screening for this allele prior to treatment administration may prove to be cost-effective as well as improve quality-of-life in people with epilepsy. Genetic testing for HLA-B*15:02 allele for predicting carbamazepine hypersensitivity, lamotrigine and phenytoin response is provided by HLA Laboratory Barnesin and by Millennium Health, USA.

A few studies also witnessed that genetic variants present in the drug metabolizing genes like CYP2C9, CYP2C19, drug transporters (ABCB1); or drug target gene SCN1A affect the binding of the drug to the receptor, and are responsible for altered drug efficacy. Around 90% metabolism of phenytoin is carried by CYP2C9 and rest 10% metabolism is carried by CYP2C19 [275]. Genetic polymorphism in CYP2C9 with variant allele *2 and *3 reduce phenytoin metabolism by 25–50% [275]. This results in increased susceptibility of those patients to phenytoin toxicity at usual administered doses. Contradictorily, one study in North Indian children showed that patients with alleles *2 and *3 had a significant increase in serum phenytoin, but without any adverse reaction [276]. Hence, CYP2C9 genotyping is done to rescue individuals for serious ADR from phenytoin. The Clinical Pharmacogenetics Implementation Consortium (CPIC) and FDA proposed that phenytoin should not be used for patients with CYP2C9 *2 and *3 variants and HLA-B*15:02 genotype [277]. Therefore, such studies help in improving the drug efficacy, alternate AED therapy administration or dosage change providing new therapeutic strategies in future. Such findings strongly establish the role of pharmacogenomics in better epilepsy treatment management and implementation in clinical settings for specific population.

6. Conclusions and Future Direction

This is a new era for epilepsy genetics. Researchers and clinicians are joining hands, who are now swiftly moving towards evidence-based therapy for epilepsy management. Through the past decade, we have made remarkable progress towards gene discovery and innovation in technological and analytic determinants of this multi-faced disease. Once the gene attributing to the monogenic or polygenic cause of disease is clearly identified therapy can be targeted towards curing the defect contributed by the gene or compensate for the impaired molecular pathway caused by any variant of that gene. May be, that is why we have achieved much farther in monogenic epilepsies relative to its polygenic counterpart. From making progress towards identifying the cause of rare and severe epilepsy types to elucidating the role of molecular players deepens the understanding of patho-physiology of the disease. Anticipating the genetic variant type associated with epilepsy, its role in pathophysiology and quantitative assessment of the role of the genetic variant role in disease risk at individual and population level is a difficult challenge. It is causing a gap at translational level to implement genetics in targeted treatment. Hence, initiating curated registries of epilepsy patients, increasing number of multi-center, randomized, controlled trials are needed. Multi center collaboration like Epilepsy Genetic Initiative is providing a platform to bridge a gap between people with epilepsy, clinician and researchers for the advancement of precision medicine in epilepsy. This governs the way for epilepsy genetics into clinics.

The future holds promise for progress in epilepsy genetic testing approaches that can be translated into improved disease diagnosis and treatment management for people with epilepsy. Large multi-national consortium and collaborative studies will generate huge data, which will be more valid and acceptable and help in making more accurate genotype–phenotype predictions. A panoramic approach is required for making advancement for precision medicine, which incorporate polygenic background and other non-genetic factors like microbiome, diet, optimal time for treatment, lifestyle like alcohol consumption and cigarette smoking which influence seizure threshold, sleep deprivation or stress should be considered which may enhance the success of the treatment [241].

A key focus is to develop a robust statistical genomic analysis approach that may consider the effect of variants in diverse population, demarcating the mutation patterns (allele frequency, its relative risk, and penetrance) contributing to the disease burden. This assures the application of genetics-based precision medicine in clinical settings. For this, it requires a multi-dimensional strategic design for effective treatment. A critical component in precision medicine would be integrating patient data obtained from multiple sources that includes genetic testing data, neuro-imaging data, biochemical profiling, comorbidities (e.g. cognitive, or psychiatric [278]), clinical and demographic details. Artificial intelligence and other technology can be used to exploit such multi-faced diseases for assessment of efficient outcomes. Developing algorithms exploiting artificial intelligence, which consider these subjective factors is inevitable. The findings and examples of genes and its variants associated with the common epilepsy phenotypes outlined in this review marks the translational potential of precision medicine into clinical care. This may guarantee the keystone for decision making in epilepsy therapy. In clinical management, genetics is potentially helping in epilepsy prognosis, diagnosis, opting a better treatment, provide provision for information regarding family planning, it is not confined to research realm only.

Although significant findings have been observed in our study, several limitations exist. In this paper, though epilepsy has been broadly categorized into common and rare epilepsies based on their prevalence, the classification of common epilepsy subtypes are largely based on available literature evidences only. Additionally, most limitations of our study originate from the available genetic studies included. Owing to different factors contributing to study heterogeneity, like different sample size, study design, heterogeneous patient cohort, diagnostic criteria, reporting biases, may tamper the statistical significance of findings, accordingly. We have reported the significant genetic findings as per each paper included. No quality assessment or statistical test was performed to evaluate each study for the homogeneity or quantify the between-study variance. Further, all the genetic association p – values reported in Table 1, are unadjusted. There can be several co-factors which, along with the risk allele, may contribute to disease susceptibility. Such confounding factors have not been covered in our review. Sensitivity analyses are performed in our study to suggest possible markers that may be considered for commercial diagnostic management. However, risk alleles alone may not provide a robust evaluation of the disease risk, especially for complex disorders like epilepsy. One major limitation of genetic association studies is contributed by the genetic heterogeneity between studies because different markers in the same genes were employed for these associations; moreover, patients with different genetic background may not be strictly comparable. Genetic markers, if reported statistically non- significant, in replication cohort or in some other population, have not been reported in this article. The role of genetic variants in mitochondrial DNA associated with epilepsy was also not been covered here. Our review is limited to studies identified only from MEDLINE (or PubMed).